introduction speech about covid 19 brainly

CBSE Class 10th
CBSE Class 12th
UP Board 10th
UP Board 12th
Bihar Board 10th
Bihar Board 12th
Top Schools in India
Top Schools in Delhi
Top Schools in Mumbai
Top Schools in Chennai
Top Schools in Hyderabad
Top Schools in Kolkata
Top Schools in Pune
Top Schools in Bangalore

Products & Resources

JEE Main Knockout April
Free Sample Papers
Free Ebooks
NCERT Notes
NCERT Syllabus
NCERT Books
RD Sharma Solutions
Navodaya Vidyalaya Admission 2024-25
NCERT Solutions
NCERT Solutions for Class 12
NCERT Solutions for Class 11
NCERT solutions for Class 10
NCERT solutions for Class 9
NCERT solutions for Class 8
NCERT Solutions for Class 7
JEE Main 2024
MHT CET 2024
JEE Advanced 2024
BITSAT 2024
View All Engineering Exams
Colleges Accepting B.Tech Applications
Top Engineering Colleges in India
Engineering Colleges in India
Engineering Colleges in Tamil Nadu
Engineering Colleges Accepting JEE Main
Top IITs in India
Top NITs in India
Top IIITs in India
JEE Main College Predictor
JEE Main Rank Predictor
MHT CET College Predictor
AP EAMCET College Predictor
GATE College Predictor
KCET College Predictor
JEE Advanced College Predictor
View All College Predictors
JEE Main Question Paper
JEE Main Cutoff
JEE Main Answer Key
JEE Main Result
Download E-Books and Sample Papers
Compare Colleges
B.Tech College Applications
JEE Advanced Registration
MAH MBA CET Exam
View All Management Exams

Colleges & Courses

MBA College Admissions
MBA Colleges in India
Top IIMs Colleges in India
Top Online MBA Colleges in India
MBA Colleges Accepting XAT Score
BBA Colleges in India
XAT College Predictor 2024
SNAP College Predictor
NMAT College Predictor
MAT College Predictor 2024
CMAT College Predictor 2024
CAT Percentile Predictor 2023
CAT 2023 College Predictor
CMAT 2024 Registration
TS ICET 2024 Registration
CMAT Exam Date 2024
MAH MBA CET Cutoff 2024
Download Helpful Ebooks
List of Popular Branches
QnA - Get answers to your doubts
IIM Fees Structure
AIIMS Nursing
Top Medical Colleges in India
Top Medical Colleges in India accepting NEET Score
Medical Colleges accepting NEET
List of Medical Colleges in India
List of AIIMS Colleges In India
Medical Colleges in Maharashtra
Medical Colleges in India Accepting NEET PG
NEET College Predictor
NEET PG College Predictor
NEET MDS College Predictor
DNB CET College Predictor
DNB PDCET College Predictor
NEET Application Form 2024
NEET PG Application Form 2024
NEET Cut off
NEET Online Preparation
Download Helpful E-books
LSAT India 2024
Colleges Accepting Admissions
Top Law Colleges in India
Law College Accepting CLAT Score
List of Law Colleges in India
Top Law Colleges in Delhi
Top Law Collages in Indore
Top Law Colleges in Chandigarh
Top Law Collages in Lucknow

Predictors & E-Books

CLAT College Predictor
MHCET Law ( 5 Year L.L.B) College Predictor
AILET College Predictor
Sample Papers
Compare Law Collages
Careers360 Youtube Channel
CLAT Syllabus 2025
CLAT Previous Year Question Paper
AIBE 18 Result 2023
NID DAT Exam
Pearl Academy Exam

Animation Courses

Animation Courses in India
Animation Courses in Bangalore
Animation Courses in Mumbai
Animation Courses in Pune
Animation Courses in Chennai
Animation Courses in Hyderabad
Design Colleges in India
Fashion Design Colleges in Bangalore
Fashion Design Colleges in Mumbai
Fashion Design Colleges in Pune
Fashion Design Colleges in Delhi
Fashion Design Colleges in Hyderabad
Fashion Design Colleges in India
Top Design Colleges in India
Free Design E-books
List of Branches
Careers360 Youtube channel
NIFT College Predictor
UCEED College Predictor
NID DAT College Predictor
IPU CET BJMC
JMI Mass Communication Entrance Exam
IIMC Entrance Exam
Media & Journalism colleges in Delhi
Media & Journalism colleges in Bangalore
Media & Journalism colleges in Mumbai
List of Media & Journalism Colleges in India
CA Intermediate
CA Foundation
CS Executive
CS Professional
Difference between CA and CS
Difference between CA and CMA
CA Full form
CMA Full form
CS Full form
CA Salary In India

Top Courses & Careers

Bachelor of Commerce (B.Com)
Master of Commerce (M.Com)
Company Secretary
Cost Accountant
Charted Accountant
Credit Manager
Financial Advisor
Top Commerce Colleges in India
Top Government Commerce Colleges in India
Top Private Commerce Colleges in India
Top M.Com Colleges in Mumbai
Top B.Com Colleges in India
IT Colleges in Tamil Nadu
IT Colleges in Uttar Pradesh
MCA Colleges in India
BCA Colleges in India

Diploma Colleges

Top Diploma Colleges in Maharashtra
UPSC IAS 2024
SSC CGL 2024
IBPS RRB 2024
Previous Year Sample Papers
Free Competition E-books
Sarkari Result
QnA- Get your doubts answered
UPSC Previous Year Sample Papers
CTET Previous Year Sample Papers
SBI Clerk Previous Year Sample Papers
NDA Previous Year Sample Papers

Upcoming Events

NDA Application Form 2024
UPSC IAS Application Form 2024
CDS Application Form 2024
CTET Admit card 2024
HP TET Result 2023
SSC GD Constable Admit Card 2024
UPTET Notification 2024
SBI Clerk Result 2024

Other Exams

SSC CHSL 2024
UP PCS 2024
UGC NET 2024
RRB NTPC 2024
IBPS PO 2024
IBPS Clerk 2024
IBPS SO 2024
Top University in USA
Top University in Canada
Top University in Ireland
Top Universities in UK
Top Universities in Australia
Best MBA Colleges in Abroad
Business Management Studies Colleges

Top Countries

Study in USA
Study in UK
Study in Canada
Study in Australia
Study in Ireland
Study in Germany
Study in China
Study in Europe

Student Visas

Student Visa Canada
Student Visa UK
Student Visa USA
Student Visa Australia
Student Visa Germany
Student Visa New Zealand
Student Visa Ireland
CUET PG 2024
IGNOU B.Ed Admission 2024
DU Admission 2024
UP B.Ed JEE 2024
LPU NEST 2024
IIT JAM 2024
IGNOU Online Admission 2024
Universities in India
Top Universities in India 2024
Top Colleges in India
Top Universities in Uttar Pradesh 2024
Top Universities in Bihar
Top Universities in Madhya Pradesh 2024
Top Universities in Tamil Nadu 2024
Central Universities in India
CUET Exam City Intimation Slip 2024
IGNOU Date Sheet
CUET Mock Test 2024
CUET Admit card 2024
CUET PG Syllabus 2024
CUET Participating Universities 2024
CUET Previous Year Question Paper
CUET Syllabus 2024 for Science Students
E-Books and Sample Papers
CUET Exam Pattern 2024
CUET Exam Date 2024
CUET Syllabus 2024
IGNOU Exam Form 2024
IGNOU Result
CUET Courses List 2024

Engineering Preparation

Knockout JEE Main 2024
Test Series JEE Main 2024
JEE Main 2024 Rank Booster

Medical Preparation

Knockout NEET 2024
Test Series NEET 2024
Rank Booster NEET 2024

Online Courses

JEE Main One Month Course
NEET One Month Course
IBSAT Free Mock Tests
IIT JEE Foundation Course
Knockout BITSAT 2024
Career Guidance Tool

Top Streams

IT & Software Certification Courses
Engineering and Architecture Certification Courses
Programming And Development Certification Courses
Business and Management Certification Courses
Marketing Certification Courses
Health and Fitness Certification Courses
Design Certification Courses

Specializations

Digital Marketing Certification Courses
Cyber Security Certification Courses
Artificial Intelligence Certification Courses
Business Analytics Certification Courses
Data Science Certification Courses
Cloud Computing Certification Courses
Machine Learning Certification Courses
View All Certification Courses
UG Degree Courses
PG Degree Courses
Short Term Courses
Free Courses
Online Degrees and Diplomas
Compare Courses

Top Providers

Coursera Courses
Udemy Courses
Edx Courses
Swayam Courses
upGrad Courses
Simplilearn Courses
Great Learning Courses

Access premium articles, webinars, resources to make the best decisions for career, course, exams, scholarships, study abroad and much more with

Plan, Prepare & Make the Best Career Choices

2 Minute Speech on Covid-19 (CoronaVirus) for Students

The year, 2019, saw the discovery of a previously unknown coronavirus illness, Covid-19 . The Coronavirus has affected the way we go about our everyday lives. This pandemic has devastated millions of people, either unwell or passed away due to the sickness. The most common symptoms of this viral illness include a high temperature, a cough, bone pain, and difficulties with the respiratory system. In addition to these symptoms, patients infected with the coronavirus may also feel weariness, a sore throat, muscular discomfort, and a loss of taste or smell.

10 Lines Speech on Covid-19 for Students

The Coronavirus is a member of a family of viruses that may infect their hosts exceptionally quickly.

Humans created the Coronavirus in the city of Wuhan in China, where it first appeared.

The first confirmed case of the Coronavirus was found in India in January in the year 2020.

Protecting ourselves against the coronavirus is essential by covering our mouths and noses when we cough or sneeze to prevent the infection from spreading.

We must constantly wash our hands with antibacterial soap and face masks to protect ourselves.

To ensure our safety, the government has ordered the whole nation's closure to halt the virus's spread.

The Coronavirus forced all our classes to be taken online, as schools and institutions were shut down.

Due to the coronavirus, everyone was instructed to stay indoors throughout the lockdown.

During this period, I spent a lot of time playing games with family members.

Even though the cases of COVID-19 are a lot less now, we should still take precautions.

Short 2-Minute Speech on Covid 19 for Students

The coronavirus, also known as Covid - 19 , causes a severe illness. Those who are exposed to it become sick in their lungs. A brand-new virus is having a devastating effect throughout the globe. It's being passed from person to person via social interaction.

The first instance of Covid - 19 was discovered in December 2019 in Wuhan, China . The World Health Organization proclaimed the covid - 19 pandemic in March 2020. It has now reached every country in the globe. Droplets produced by an infected person's cough or sneeze might infect those nearby.

The severity of Covid-19 symptoms varies widely. Symptoms aren't always present. The typical symptoms are high temperatures, a dry cough, and difficulty breathing. Covid - 19 individuals also exhibit other symptoms such as weakness, a sore throat, muscular soreness, and a diminished sense of smell and taste.

Vaccination has been produced by many countries but the effectiveness of them is different for every individual. The only treatment then is to avoid contracting in the first place. We can accomplish that by following these protocols—

Put on a mask to hide your face. Use soap and hand sanitiser often to keep germs at bay.

Keep a distance of 5 to 6 feet at all times.

Never put your fingers in your mouth or nose.

Long 2-Minute Speech on Covid 19 for Students

As students, it's important for us to understand the gravity of the situation regarding the Covid-19 pandemic and the impact it has on our communities and the world at large. In this speech, I will discuss the real-world examples of the effects of the pandemic and its impact on various aspects of our lives.

Impact on Economy | The Covid-19 pandemic has had a significant impact on the global economy. We have seen how businesses have been forced to close their doors, leading to widespread job loss and economic hardship. Many individuals and families have been struggling to make ends meet, and this has led to a rise in poverty and inequality.

Impact on Healthcare Systems | The pandemic has also put a strain on healthcare systems around the world. Hospitals have been overwhelmed with patients, and healthcare workers have been stretched to their limits. This has highlighted the importance of investing in healthcare systems and ensuring that they are prepared for future crises.

Impact on Education | The pandemic has also affected the education system, with schools and universities being closed around the world. This has led to a shift towards online learning and the use of technology to continue education remotely. However, it has also highlighted the digital divide, with many students from low-income backgrounds facing difficulties in accessing online learning.

Impact on Mental Health | The pandemic has not only affected our physical health but also our mental health. We have seen how the isolation and uncertainty caused by the pandemic have led to an increase in stress, anxiety, and depression. It's important that we take care of our mental health and support each other during this difficult time.

Real-life Story of a Student

John is a high school student who was determined to succeed despite the struggles brought on by the Covid-19 pandemic.

John's school closed down in the early days of the pandemic, and he quickly found himself struggling to adjust to online learning. Without the structure and support of in-person classes, John found it difficult to stay focused and motivated. He also faced challenges at home, as his parents were both essential workers and were often not available to help him with his schoolwork.

Despite these struggles, John refused to let the pandemic defeat him. He made a schedule for himself, to stay on top of his assignments and set goals for himself. He also reached out to his teachers for additional support, and they were more than happy to help.

John also found ways to stay connected with his classmates and friends, even though they were physically apart. They formed a study group and would meet regularly over Zoom to discuss their assignments and provide each other with support.

Thanks to his hard work and determination, John was able to maintain good grades and even improved in some subjects. He graduated high school on time, and was even accepted into his first-choice college.

John's story is a testament to the resilience and determination of students everywhere. Despite the challenges brought on by the pandemic, he was able to succeed and achieve his goals. He shows us that with hard work, determination, and support, we can overcome even the toughest of obstacles.

Explore Career Options (By Industry)

Construction
Entertainment
Manufacturing
Information Technology

Data Administrator

Database professionals use software to store and organise data such as financial information, and customer shipping records. Individuals who opt for a career as data administrators ensure that data is available for users and secured from unauthorised sales. DB administrators may work in various types of industries. It may involve computer systems design, service firms, insurance companies, banks and hospitals.

Bio Medical Engineer

The field of biomedical engineering opens up a universe of expert chances. An Individual in the biomedical engineering career path work in the field of engineering as well as medicine, in order to find out solutions to common problems of the two fields. The biomedical engineering job opportunities are to collaborate with doctors and researchers to develop medical systems, equipment, or devices that can solve clinical problems. Here we will be discussing jobs after biomedical engineering, how to get a job in biomedical engineering, biomedical engineering scope, and salary.

Ethical Hacker

A career as ethical hacker involves various challenges and provides lucrative opportunities in the digital era where every giant business and startup owns its cyberspace on the world wide web. Individuals in the ethical hacker career path try to find the vulnerabilities in the cyber system to get its authority. If he or she succeeds in it then he or she gets its illegal authority. Individuals in the ethical hacker career path then steal information or delete the file that could affect the business, functioning, or services of the organization.

GIS officer work on various GIS software to conduct a study and gather spatial and non-spatial information. GIS experts update the GIS data and maintain it. The databases include aerial or satellite imagery, latitudinal and longitudinal coordinates, and manually digitized images of maps. In a career as GIS expert, one is responsible for creating online and mobile maps.

Data Analyst

The invention of the database has given fresh breath to the people involved in the data analytics career path. Analysis refers to splitting up a whole into its individual components for individual analysis. Data analysis is a method through which raw data are processed and transformed into information that would be beneficial for user strategic thinking.

Data are collected and examined to respond to questions, evaluate hypotheses or contradict theories. It is a tool for analyzing, transforming, modeling, and arranging data with useful knowledge, to assist in decision-making and methods, encompassing various strategies, and is used in different fields of business, research, and social science.

Geothermal Engineer

Individuals who opt for a career as geothermal engineers are the professionals involved in the processing of geothermal energy. The responsibilities of geothermal engineers may vary depending on the workplace location. Those who work in fields design facilities to process and distribute geothermal energy. They oversee the functioning of machinery used in the field.

Database Architect

If you are intrigued by the programming world and are interested in developing communications networks then a career as database architect may be a good option for you. Data architect roles and responsibilities include building design models for data communication networks. Wide Area Networks (WANs), local area networks (LANs), and intranets are included in the database networks. It is expected that database architects will have in-depth knowledge of a company's business to develop a network to fulfil the requirements of the organisation. Stay tuned as we look at the larger picture and give you more information on what is db architecture, why you should pursue database architecture, what to expect from such a degree and what your job opportunities will be after graduation. Here, we will be discussing how to become a data architect. Students can visit NIT Trichy , IIT Kharagpur , JMI New Delhi .

Remote Sensing Technician

Individuals who opt for a career as a remote sensing technician possess unique personalities. Remote sensing analysts seem to be rational human beings, they are strong, independent, persistent, sincere, realistic and resourceful. Some of them are analytical as well, which means they are intelligent, introspective and inquisitive.

Remote sensing scientists use remote sensing technology to support scientists in fields such as community planning, flight planning or the management of natural resources. Analysing data collected from aircraft, satellites or ground-based platforms using statistical analysis software, image analysis software or Geographic Information Systems (GIS) is a significant part of their work. Do you want to learn how to become remote sensing technician? There's no need to be concerned; we've devised a simple remote sensing technician career path for you. Scroll through the pages and read.

Budget Analyst

Budget analysis, in a nutshell, entails thoroughly analyzing the details of a financial budget. The budget analysis aims to better understand and manage revenue. Budget analysts assist in the achievement of financial targets, the preservation of profitability, and the pursuit of long-term growth for a business. Budget analysts generally have a bachelor's degree in accounting, finance, economics, or a closely related field. Knowledge of Financial Management is of prime importance in this career.

Underwriter

An underwriter is a person who assesses and evaluates the risk of insurance in his or her field like mortgage, loan, health policy, investment, and so on and so forth. The underwriter career path does involve risks as analysing the risks means finding out if there is a way for the insurance underwriter jobs to recover the money from its clients. If the risk turns out to be too much for the company then in the future it is an underwriter who will be held accountable for it. Therefore, one must carry out his or her job with a lot of attention and diligence.

Finance Executive

Product manager.

A Product Manager is a professional responsible for product planning and marketing. He or she manages the product throughout the Product Life Cycle, gathering and prioritising the product. A product manager job description includes defining the product vision and working closely with team members of other departments to deliver winning products.

Operations Manager

Individuals in the operations manager jobs are responsible for ensuring the efficiency of each department to acquire its optimal goal. They plan the use of resources and distribution of materials. The operations manager's job description includes managing budgets, negotiating contracts, and performing administrative tasks.

Stock Analyst

Individuals who opt for a career as a stock analyst examine the company's investments makes decisions and keep track of financial securities. The nature of such investments will differ from one business to the next. Individuals in the stock analyst career use data mining to forecast a company's profits and revenues, advise clients on whether to buy or sell, participate in seminars, and discussing financial matters with executives and evaluate annual reports.

A Researcher is a professional who is responsible for collecting data and information by reviewing the literature and conducting experiments and surveys. He or she uses various methodological processes to provide accurate data and information that is utilised by academicians and other industry professionals. Here, we will discuss what is a researcher, the researcher's salary, types of researchers.

Welding Engineer

Welding Engineer Job Description: A Welding Engineer work involves managing welding projects and supervising welding teams. He or she is responsible for reviewing welding procedures, processes and documentation. A career as Welding Engineer involves conducting failure analyses and causes on welding issues.

Transportation Planner

A career as Transportation Planner requires technical application of science and technology in engineering, particularly the concepts, equipment and technologies involved in the production of products and services. In fields like land use, infrastructure review, ecological standards and street design, he or she considers issues of health, environment and performance. A Transportation Planner assigns resources for implementing and designing programmes. He or she is responsible for assessing needs, preparing plans and forecasts and compliance with regulations.

Environmental Engineer

Individuals who opt for a career as an environmental engineer are construction professionals who utilise the skills and knowledge of biology, soil science, chemistry and the concept of engineering to design and develop projects that serve as solutions to various environmental problems.

Safety Manager

A Safety Manager is a professional responsible for employee’s safety at work. He or she plans, implements and oversees the company’s employee safety. A Safety Manager ensures compliance and adherence to Occupational Health and Safety (OHS) guidelines.

Conservation Architect

A Conservation Architect is a professional responsible for conserving and restoring buildings or monuments having a historic value. He or she applies techniques to document and stabilise the object’s state without any further damage. A Conservation Architect restores the monuments and heritage buildings to bring them back to their original state.

Structural Engineer

A Structural Engineer designs buildings, bridges, and other related structures. He or she analyzes the structures and makes sure the structures are strong enough to be used by the people. A career as a Structural Engineer requires working in the construction process. It comes under the civil engineering discipline. A Structure Engineer creates structural models with the help of computer-aided design software.

Highway Engineer

Highway Engineer Job Description: A Highway Engineer is a civil engineer who specialises in planning and building thousands of miles of roads that support connectivity and allow transportation across the country. He or she ensures that traffic management schemes are effectively planned concerning economic sustainability and successful implementation.

Field Surveyor

Are you searching for a Field Surveyor Job Description? A Field Surveyor is a professional responsible for conducting field surveys for various places or geographical conditions. He or she collects the required data and information as per the instructions given by senior officials.

Orthotist and Prosthetist

Orthotists and Prosthetists are professionals who provide aid to patients with disabilities. They fix them to artificial limbs (prosthetics) and help them to regain stability. There are times when people lose their limbs in an accident. In some other occasions, they are born without a limb or orthopaedic impairment. Orthotists and prosthetists play a crucial role in their lives with fixing them to assistive devices and provide mobility.

Pathologist

A career in pathology in India is filled with several responsibilities as it is a medical branch and affects human lives. The demand for pathologists has been increasing over the past few years as people are getting more aware of different diseases. Not only that, but an increase in population and lifestyle changes have also contributed to the increase in a pathologist’s demand. The pathology careers provide an extremely huge number of opportunities and if you want to be a part of the medical field you can consider being a pathologist. If you want to know more about a career in pathology in India then continue reading this article.

Veterinary Doctor

Speech therapist, gynaecologist.

Gynaecology can be defined as the study of the female body. The job outlook for gynaecology is excellent since there is evergreen demand for one because of their responsibility of dealing with not only women’s health but also fertility and pregnancy issues. Although most women prefer to have a women obstetrician gynaecologist as their doctor, men also explore a career as a gynaecologist and there are ample amounts of male doctors in the field who are gynaecologists and aid women during delivery and childbirth.

Audiologist

The audiologist career involves audiology professionals who are responsible to treat hearing loss and proactively preventing the relevant damage. Individuals who opt for a career as an audiologist use various testing strategies with the aim to determine if someone has a normal sensitivity to sounds or not. After the identification of hearing loss, a hearing doctor is required to determine which sections of the hearing are affected, to what extent they are affected, and where the wound causing the hearing loss is found. As soon as the hearing loss is identified, the patients are provided with recommendations for interventions and rehabilitation such as hearing aids, cochlear implants, and appropriate medical referrals. While audiology is a branch of science that studies and researches hearing, balance, and related disorders.

An oncologist is a specialised doctor responsible for providing medical care to patients diagnosed with cancer. He or she uses several therapies to control the cancer and its effect on the human body such as chemotherapy, immunotherapy, radiation therapy and biopsy. An oncologist designs a treatment plan based on a pathology report after diagnosing the type of cancer and where it is spreading inside the body.

Are you searching for an ‘Anatomist job description’? An Anatomist is a research professional who applies the laws of biological science to determine the ability of bodies of various living organisms including animals and humans to regenerate the damaged or destroyed organs. If you want to know what does an anatomist do, then read the entire article, where we will answer all your questions.

For an individual who opts for a career as an actor, the primary responsibility is to completely speak to the character he or she is playing and to persuade the crowd that the character is genuine by connecting with them and bringing them into the story. This applies to significant roles and littler parts, as all roles join to make an effective creation. Here in this article, we will discuss how to become an actor in India, actor exams, actor salary in India, and actor jobs.

Individuals who opt for a career as acrobats create and direct original routines for themselves, in addition to developing interpretations of existing routines. The work of circus acrobats can be seen in a variety of performance settings, including circus, reality shows, sports events like the Olympics, movies and commercials. Individuals who opt for a career as acrobats must be prepared to face rejections and intermittent periods of work. The creativity of acrobats may extend to other aspects of the performance. For example, acrobats in the circus may work with gym trainers, celebrities or collaborate with other professionals to enhance such performance elements as costume and or maybe at the teaching end of the career.

Video Game Designer

Career as a video game designer is filled with excitement as well as responsibilities. A video game designer is someone who is involved in the process of creating a game from day one. He or she is responsible for fulfilling duties like designing the character of the game, the several levels involved, plot, art and similar other elements. Individuals who opt for a career as a video game designer may also write the codes for the game using different programming languages.

Depending on the video game designer job description and experience they may also have to lead a team and do the early testing of the game in order to suggest changes and find loopholes.

Radio Jockey

Radio Jockey is an exciting, promising career and a great challenge for music lovers. If you are really interested in a career as radio jockey, then it is very important for an RJ to have an automatic, fun, and friendly personality. If you want to get a job done in this field, a strong command of the language and a good voice are always good things. Apart from this, in order to be a good radio jockey, you will also listen to good radio jockeys so that you can understand their style and later make your own by practicing.

A career as radio jockey has a lot to offer to deserving candidates. If you want to know more about a career as radio jockey, and how to become a radio jockey then continue reading the article.

Choreographer

The word “choreography" actually comes from Greek words that mean “dance writing." Individuals who opt for a career as a choreographer create and direct original dances, in addition to developing interpretations of existing dances. A Choreographer dances and utilises his or her creativity in other aspects of dance performance. For example, he or she may work with the music director to select music or collaborate with other famous choreographers to enhance such performance elements as lighting, costume and set design.

Social Media Manager

A career as social media manager involves implementing the company’s or brand’s marketing plan across all social media channels. Social media managers help in building or improving a brand’s or a company’s website traffic, build brand awareness, create and implement marketing and brand strategy. Social media managers are key to important social communication as well.

Photographer

Photography is considered both a science and an art, an artistic means of expression in which the camera replaces the pen. In a career as a photographer, an individual is hired to capture the moments of public and private events, such as press conferences or weddings, or may also work inside a studio, where people go to get their picture clicked. Photography is divided into many streams each generating numerous career opportunities in photography. With the boom in advertising, media, and the fashion industry, photography has emerged as a lucrative and thrilling career option for many Indian youths.

An individual who is pursuing a career as a producer is responsible for managing the business aspects of production. They are involved in each aspect of production from its inception to deception. Famous movie producers review the script, recommend changes and visualise the story.

They are responsible for overseeing the finance involved in the project and distributing the film for broadcasting on various platforms. A career as a producer is quite fulfilling as well as exhaustive in terms of playing different roles in order for a production to be successful. Famous movie producers are responsible for hiring creative and technical personnel on contract basis.

Copy Writer

In a career as a copywriter, one has to consult with the client and understand the brief well. A career as a copywriter has a lot to offer to deserving candidates. Several new mediums of advertising are opening therefore making it a lucrative career choice. Students can pursue various copywriter courses such as Journalism , Advertising , Marketing Management . Here, we have discussed how to become a freelance copywriter, copywriter career path, how to become a copywriter in India, and copywriting career outlook.

In a career as a vlogger, one generally works for himself or herself. However, once an individual has gained viewership there are several brands and companies that approach them for paid collaboration. It is one of those fields where an individual can earn well while following his or her passion.

Ever since internet costs got reduced the viewership for these types of content has increased on a large scale. Therefore, a career as a vlogger has a lot to offer. If you want to know more about the Vlogger eligibility, roles and responsibilities then continue reading the article.

For publishing books, newspapers, magazines and digital material, editorial and commercial strategies are set by publishers. Individuals in publishing career paths make choices about the markets their businesses will reach and the type of content that their audience will be served. Individuals in book publisher careers collaborate with editorial staff, designers, authors, and freelance contributors who develop and manage the creation of content.

Careers in journalism are filled with excitement as well as responsibilities. One cannot afford to miss out on the details. As it is the small details that provide insights into a story. Depending on those insights a journalist goes about writing a news article. A journalism career can be stressful at times but if you are someone who is passionate about it then it is the right choice for you. If you want to know more about the media field and journalist career then continue reading this article.

Individuals in the editor career path is an unsung hero of the news industry who polishes the language of the news stories provided by stringers, reporters, copywriters and content writers and also news agencies. Individuals who opt for a career as an editor make it more persuasive, concise and clear for readers. In this article, we will discuss the details of the editor's career path such as how to become an editor in India, editor salary in India and editor skills and qualities.

Individuals who opt for a career as a reporter may often be at work on national holidays and festivities. He or she pitches various story ideas and covers news stories in risky situations. Students can pursue a BMC (Bachelor of Mass Communication) , B.M.M. (Bachelor of Mass Media) , or MAJMC (MA in Journalism and Mass Communication) to become a reporter. While we sit at home reporters travel to locations to collect information that carries a news value.

Corporate Executive

Are you searching for a Corporate Executive job description? A Corporate Executive role comes with administrative duties. He or she provides support to the leadership of the organisation. A Corporate Executive fulfils the business purpose and ensures its financial stability. In this article, we are going to discuss how to become corporate executive.

Multimedia Specialist

A multimedia specialist is a media professional who creates, audio, videos, graphic image files, computer animations for multimedia applications. He or she is responsible for planning, producing, and maintaining websites and applications.

Quality Controller

A quality controller plays a crucial role in an organisation. He or she is responsible for performing quality checks on manufactured products. He or she identifies the defects in a product and rejects the product.

A quality controller records detailed information about products with defects and sends it to the supervisor or plant manager to take necessary actions to improve the production process.

Production Manager

A QA Lead is in charge of the QA Team. The role of QA Lead comes with the responsibility of assessing services and products in order to determine that he or she meets the quality standards. He or she develops, implements and manages test plans.

Process Development Engineer

The Process Development Engineers design, implement, manufacture, mine, and other production systems using technical knowledge and expertise in the industry. They use computer modeling software to test technologies and machinery. An individual who is opting career as Process Development Engineer is responsible for developing cost-effective and efficient processes. They also monitor the production process and ensure it functions smoothly and efficiently.

AWS Solution Architect

An AWS Solution Architect is someone who specializes in developing and implementing cloud computing systems. He or she has a good understanding of the various aspects of cloud computing and can confidently deploy and manage their systems. He or she troubleshoots the issues and evaluates the risk from the third party.

Azure Administrator

An Azure Administrator is a professional responsible for implementing, monitoring, and maintaining Azure Solutions. He or she manages cloud infrastructure service instances and various cloud servers as well as sets up public and private cloud systems.

Computer Programmer

Careers in computer programming primarily refer to the systematic act of writing code and moreover include wider computer science areas. The word 'programmer' or 'coder' has entered into practice with the growing number of newly self-taught tech enthusiasts. Computer programming careers involve the use of designs created by software developers and engineers and transforming them into commands that can be implemented by computers. These commands result in regular usage of social media sites, word-processing applications and browsers.

Information Security Manager

Individuals in the information security manager career path involves in overseeing and controlling all aspects of computer security. The IT security manager job description includes planning and carrying out security measures to protect the business data and information from corruption, theft, unauthorised access, and deliberate attack

ITSM Manager

Automation test engineer.

An Automation Test Engineer job involves executing automated test scripts. He or she identifies the project’s problems and troubleshoots them. The role involves documenting the defect using management tools. He or she works with the application team in order to resolve any issues arising during the testing process.

Applications for Admissions are open.

Aakash iACST Scholarship Test 2024

Get up to 90% scholarship on NEET, JEE & Foundation courses

JEE Main Important Chemistry formulas

As per latest 2024 syllabus. Chemistry formulas, equations, & laws of class 11 & 12th chapters

PACE IIT & Medical, Financial District, Hyd

Enrol in PACE IIT & Medical, Financial District, Hyd for JEE/NEET preparation

ALLEN JEE Exam Prep

Start your JEE preparation with ALLEN

ALLEN NEET Coaching

Ace your NEET preparation with ALLEN Online Programs

SAT® | CollegeBoard

Everything about Education

Latest updates, Exclusive Content, Webinars and more.

Download Careers360 App's

Regular exam updates, QnA, Predictors, College Applications & E-books now on your Mobile

Cetifications

We Appeared in

A monthly newsletter from the National Institutes of Health, part of the U.S. Department of Health and Human Services

Search form

Print this issue

Understanding COVID-19

How To Protect Yourself During the Pandemic

Illustration of two men wearing masks while sitting on park benches six feet apart

COVID-19 has claimed millions of lives around the world. But we learn more about this disease every day. Scientists are developing tools that promise to slow and eventually help us overcome the pandemic.

COVID-19 is caused by a new coronavirus called SARS-CoV-2. There are many types of coronaviruses. Some cause the common cold. Others have led to fatal disease outbreaks. These include severe acute respiratory syndrome (SARS) in 2003, Middle East respiratory syndrome (MERS) in 2012, and now COVID-19.

Coronaviruses are named for the crown-like spikes on their surface. (Corona means crown.) The viruses use the spikes to help get inside your body’s cells. Once inside, they replicate, or make copies of themselves.

Scientists have learned how to turn these spikes against the virus through vaccines and treatments. They’ve also learned what you can do to protect yourself from the virus.

Protecting Yourself

You’re most likely to get COVID-19 through close contact with someone who’s infected. Coughing, sneezing, talking, and breathing produce small droplets of liquid. These are called respiratory droplets. They travel through the air and can be inhaled by someone else.

“COVID-19 is spread mainly through exposure to respiratory droplets that tend to drop within six feet,” says Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases. That’s why it’s important to stay at least six feet (about two arm lengths) away from people who don’t live with you.

“Surfaces can be contaminated. But it is likely that this is a less common cause of infection rather than person-to-person directly,” Fauci says.

You can protect yourself and others by wearing a mask. Choose one that has at least two layers of fabric. Make sure that the mask covers your mouth and nose and doesn’t leak air around the edges.

“There’s very little transmission in places where masks are worn,” says Dr. Ben Cowling at the University of Hong Kong who studies how viruses spread. Cowling found that infections were most often spread in settings where masks aren’t worn.

“Masks work. But even with mandatory masking, you still need social distancing as well,” he says. You can lower your risk by avoiding crowds. Crowds increase the risk of coming in contact with someone who has COVID-19.

What to Look For

Common symptoms of COVID-19 include fever, cough, headaches, fatigue, and muscle or body aches. People with COVID-19 may also lose their sense of smell or taste. Symptoms usually appear two to 14 days after being exposed to the virus.

But even people who don’t seem sick can still infect others. The CDC estimates that 50% of infections are spread by people with no symptoms. While some with this virus develop life-threatening illness, others have mild symptoms, and some never develop any.

Catching the virus is more dangerous for some groups of people. This includes older adults and people with certain medical conditions. These medical conditions include obesity, diabetes, heart and lung disease, and asthma. About 40% of Americans have at least one of these risk factors.

Getting Treatment

Better COVID-19 treatments mean that fewer people now get severely sick if they catch the virus. Scientists have been working to test available drugs against the virus. They’ve found at least two that can help people who are hospitalized with the virus.

A drug called remdesivir can reduce the time a patient spends in the hospital. A steroid called dexamethasone helps stop the immune system The system that protects your body from invading viruses, bacteria, and other microscopic threats. from reacting too strongly to the virus. That can damage body tissues and organs.

Antibody treatments are also available. Antibodies are proteins that your body makes to fight germs. Scientists have learned how to make them in the lab. Antibody treatments can block SARS-CoV-2 to prevent the illness from getting worse. They seem to have the most benefit when given early in the disease.

“Antibody treatments really do have the potential to help people, especially for treating individuals who are not yet hospitalized,” says Dr. Mark Heise, who studies the genetics of viruses at the University of North Carolina at Chapel Hill. Heise is working to develop mouse models to test treatments and vaccines.

Studies are now testing combinations of treatments. “Combining drugs that target both the virus and the person’s immune response may help treat COVID-19,” says Heise. Scientists are also looking for new drugs that better target the virus.

A Shot of Hope: Vaccines

It used to take a decade or more to develop a new vaccine. In this pandemic, scientists created COVID-19 vaccines in less than a year.

The first two vaccines approved for emergency use are from Moderna and Pfizer/BioNTech. Moderna’s vaccine was co-developed with NIH scientists. Both are a new type of vaccine called mRNA vaccines. mRNA carries the genetic information for your body to make proteins.

The vaccines direct the body’s cells to make a piece of the virus called the spike protein. These proteins can’t cause illness by themselves. But they teach your immune system to make antibodies against the protein. If you encounter the virus later, the antibodies provide protection against it.

The mRNA vaccines now available were shown to be more than 90% effective in large clinical trials. They can cause side effects—such as fatigue, muscle aches, joint pain, and headache. But both vaccines were found to be safe in the clinical trials.

“Get vaccinated. The vaccines are safe. They’re incredibly effective,” says Dr. Jason McLellan, an expert on coronaviruses at the University of Texas at Austin. McLellan’s research was critical in developing these vaccines. His team, along with NIH scientists, figured out how to lock the shape of the spike protein to make the most effective antibodies.

As the pandemic has gone on, new versions of the virus, or variants, have appeared. “We’re all very confident that vaccines will continue to work well against these variants,” McLellan says. “Vaccination also helps stop the development of new variants, because it provides fewer opportunities for the virus to change as it replicates.”

Many people will need to be vaccinated for the pandemic to end. Fauci estimates that 70% to 85% of the U.S. population will need to be vaccinated to get “herd immunity.” That’s the point where enough people are immune to the virus to prevent its spread. That’s important because it protects vulnerable people who can’t get vaccinated.

“It is my hope that all Americans will protect themselves by getting vaccinated when the vaccine becomes available to them,” Fauci says. “That is how our country will begin to heal and move forward.”

About COVID-19

What is covid-19.

COVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2. It can be very contagious and spreads quickly. Over one million people have died from COVID-19 in the United States.

COVID-19 most often causes respiratory symptoms that can feel much like a cold, the flu, or pneumonia. COVID-19 may attack more than your lungs and respiratory system. Other parts of your body may also be affected by the disease. Most people with COVID-19 have mild symptoms, but some people become severely ill.

Some people including those with minor or no symptoms will develop Post-COVID Conditions – also called “Long COVID.”

How does COVID-19 spread?

COVID-19 spreads when an infected person breathes out droplets and very small particles that contain the virus. Other people can breathe in these droplets and particles, or these droplets and particles can land on their eyes, nose, or mouth. In some circumstances, these droplets may contaminate surfaces they touch.

Anyone infected with COVID-19 can spread it, even if they do NOT have symptoms.

The risk of animals spreading the virus that causes COVID-19 to people is low. The virus can spread from people to animals during close contact. People with suspected or confirmed COVID-19 should avoid contact with animals.

What are antibodies and how do they help protect me?

Antibodies are proteins your immune system makes to help fight infection and protect you from getting sick in the future. A positive antibody test result can help identify someone who has had COVID-19 in the past or has been vaccinated against COVID-19. Studies show that people who have antibodies from an infection with the virus that causes COVID-19 can improve their level of protection by getting vaccinated.

Who is at risk of severe illness from COVID-19?

Some people are more likely than others to get very sick if they get COVID-19. This includes people who are older , are immunocompromised (have a weakened immune system), have certain disabilities , or have underlying health conditions . Understanding your COVID-19 risk and the risks that might affect others can help you make decisions to protect yourself and others .

What are ways to prevent COVID-19?

There are many actions you can take to help protect you, your household, and your community from COVID-19. CDC’s Respiratory Virus Guidance provides actions you can take to help protect yourself and others from health risks caused by respiratory viruses, including COVID-19. These actions include steps you can take to lower the risk of COVID-19 transmission (catching and spreading COVID-19) and lower the risk of severe illness if you get sick.

CDC recommends that you

Stay up to date with COVID-19 vaccines
Practice good hygiene (practices that improve cleanliness)
Take steps for cleaner air
Stay home when sick
Seek health care promptly for testing and treatment when you are sick if you have risk factors for severe illness . Treatment may help lower your risk of severe illness.

Masks , physical distancing , and tests can provide additional layers of protection.

What are variants of COVID-19?

Viruses are constantly changing, including the virus that causes COVID-19. These changes occur over time and can lead to new strains of the virus or variants of COVID-19 . Slowing the spread of the virus, by protecting yourself and others , can help slow new variants from developing. CDC is working with state and local public health officials to monitor the spread of all variants, including Omicron.

COVID-19 Testing
COVID-19 Vaccines
Preventing Respiratory Viruses
Reinfection
Difference Between Flu and COVID-19
COVID Data Tracker

Search for and find historical COVID-19 pages and files. Please note the content on these pages and files is no longer being updated and may be out of date.

Visit archive.cdc.gov for a historical snapshot of the COVID-19 website, capturing the end of the Federal Public Health Emergency on June 28, 2023.
Visit the dynamic COVID-19 collection to search the COVID-19 website as far back as July 30, 2021.

To receive email updates about COVID-19, enter your email address:

Exit Notification / Disclaimer Policy

The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

Discussions
Certificates
Collab Space
Course Details
Announcements

An error occurred while loading the video player, or it takes a long time to initialize. You can try clearing your browser cache. Please try again later and contact the helpdesk if the problem persists.

Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).

A novel coronavirus (COVID-19) was identified in 2019 in Wuhan, China. This is a new coronavirus that has not been previously identified in humans.

This course provides a general introduction to COVID-19 and emerging respiratory viruses and is intended for public health professionals, incident managers and personnel working for the United Nations, international organizations and NGOs.

As the official disease name was established after material creation, any mention of nCoV refers to COVID-19, the infectious disease caused by the most recently discovered coronavirus.

Please note that the content of this course is currently being revised to reflect the most recent guidance. You can find updated information on certain COVID-19-related topics in the following courses: Vaccination: COVID-19 vaccines channel IPC measures: IPC for COVID-19 Antigen rapid diagnostic testing: 1) SARS-CoV-2 antigen rapid diagnostic testing ; 2) Key considerations for SARS-CoV-2 antigen RDT implementation

Please note: These materials were last updated on 16/12/2020.

Course contents

Emerging respiratory viruses, including covid-19: introduction:, module 1: introduction to emerging respiratory viruses, including covid-19:, module 2: detecting emerging respiratory viruses, including covid-19: surveillance:, module 3: detecting emerging respiratory viruses, including covid-19: laboratory investigations:, module 4: risk communication :, module 5 : community engagement:, module 6: preventing and responding to an emerging respiratory virus, including covid-19:, enroll me for this course, certificate requirements.

Gain a Record of Achievement by earning at least 80% of the maximum number of points from all graded assignments.

Mobile Menu Overlay

The White House 1600 Pennsylvania Ave NW Washington, DC 20500

Remarks by President Biden on the COVID- ⁠ 19 Response and Vaccination Program

South Court Auditorium Eisenhower Executive Office Building

12:54 P.M. EDT

THE PRESIDENT: Good afternoon. I’ve just been briefed by my COVID-19 team on the progress we’re making in our fight against the virus. Today, I want to provide a brief update on my plan that I announced in early September to accelerate the path out of the pandemic. It’s working. We’re making progress. Nationally, daily cases are down 47 percent; hospitalizations are down 38 percent over the past six weeks. Over the past two weeks, most of the country has improved as well. Case rates are declining in 39 states and hospital rates are declining in 38 states. We’re down to 66 million — it’s still an unacceptably high number — of unvaccinated people from almost 100 million in July. That’s important. It’s important progress. But it’s not — now is not the time to let up. We have a lot more to do. We’re in a very critical period as we work to turn the corner on COVID-19. First, we have to do more to vaccinate the 66 million unvaccinated people in America. It’s essential. The vaccine requirements that we started rolling out in the summer are working. They’re working. The Labor Department is going to soon be issuing an emergency rule for companies with 100 or more employees to implement vaccination requirements in their — among their workforce. Every day, we see more businesses implementing vaccination requirements, and the mounting data that shows they work. Businesses and organizations that are implementing requirements are seeing their vaccination rates rise by an average of 20 percent or more to well over 90 percent — the number of employees vaccinated. Let’s be clear: Vaccination requirements should not be another issue that divides us. That’s why we continue to battle the misinformation that’s out there, and companies and communities are setting up their — stepping up as well to combat these — the misinformation. Southwest Airlines at — the head of the pilot — the head of the pilot’s union and its CEO dismissed critics who claim vaccination mandates contributed to flight disruptions. School board members, religious leaders, and doctors across the country are fighting misinformation and educating people about the importance of vaccines. All of these efforts are going to help us continue moving the dial to eliminate this disease. Second, we’re going to continue protecting the vaccinated. This work — this week, the Food and Drug Administration and — the FDA is reviewing the data on Moderna and Johnson & Johnson boosters. We expect a final decision from the FDA and the Centers for Disease Control and Prevention -– the CDC –- in the next couple of weeks. If they authorize the boosters, which will be strictly made based on the science — that decision will be based on the science — this will mean all three vaccines will be available for boosters. Already, more than 1 out of 3 eligible seniors have gotten their third shot — the booster. And we’re going to continue to provide that additional protection to seniors and others as we — as we head into the holidays.

These boosters are free. I’ll say it again: They’re free, available, and convenient to get. Third point I’d like to make: We need to continue to keep our schools and our students safe. Ninety-six percent of school districts are fully open with children back in the classroom and — for in-person learning. We have been able to do this because we’ve provided our schools the resources they need to protect children and the educators, as well as the staff that works in the schools. We’ve been encouraging schools to implement important health measures like masking, testing, and getting everyone vaccinated who is eligible to be vaccinated. Now, I know parents out there are anxiously waiting for a vaccine for children ages 5 to 11. The good news is the FDA and outside experts from the CDC are set to make its determination as to whether the vaccine will be authorized for that age range in the next few weeks. If authorized, we are ready. We have purchased enough vaccines for all children between the ages of 5 and 11 in the United States. It will be — it will be convenient for parents to get their children vaccinated at trusted locations, and families will be able to sleep easier at night knowing their kids are protected as well. Let me close with this: The plan I laid out in September is working. We’re headed in the right direction. We have critical work to do, but we can’t let up now. My team and I are doing everything we can. But I’m calling on more businesses to step up. I’m calling on more parents to get their children vaccinated when they are eligible. And I’m asking everyone — everyone who hasn’t gotten vaccinated: Please get vaccinated. That’s how we put this pandemic behind us and accelerate our economic recovery. We can do this. I’ve said many times: God bless you all, and may God protect our troops. Thank you very much. 1:00 P.M. EDT

Stay Connected

We'll be in touch with the latest information on how President Biden and his administration are working for the American people, as well as ways you can get involved and help our country build back better.

Opt in to send and receive text messages from President Biden.

MINI REVIEW article

Covid-19: emergence, spread, possible treatments, and global burden.

$\nRaghuvir Keni$

1 Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India
2 Department of Health Sciences, School of Education and Health, Cape Breton University, Sydney, NS, Canada

The Coronavirus (CoV) is a large family of viruses known to cause illnesses ranging from the common cold to acute respiratory tract infection. The severity of the infection may be visible as pneumonia, acute respiratory syndrome, and even death. Until the outbreak of SARS, this group of viruses was greatly overlooked. However, since the SARS and MERS outbreaks, these viruses have been studied in greater detail, propelling the vaccine research. On December 31, 2019, mysterious cases of pneumonia were detected in the city of Wuhan in China's Hubei Province. On January 7, 2020, the causative agent was identified as a new coronavirus (2019-nCoV), and the disease was later named as COVID-19 by the WHO. The virus spread extensively in the Wuhan region of China and has gained entry to over 210 countries and territories. Though experts suspected that the virus is transmitted from animals to humans, there are mixed reports on the origin of the virus. There are no treatment options available for the virus as such, limited to the use of anti-HIV drugs and/or other antivirals such as Remdesivir and Galidesivir. For the containment of the virus, it is recommended to quarantine the infected and to follow good hygiene practices. The virus has had a significant socio-economic impact globally. Economically, China is likely to experience a greater setback than other countries from the pandemic due to added trade war pressure, which have been discussed in this paper.

Introduction

Coronaviridae is a family of viruses with a positive-sense RNA that possess an outer viral coat. When looked at with the help of an electron microscope, there appears to be a unique corona around it. This family of viruses mainly cause respiratory diseases in humans, in the forms of common cold or pneumonia as well as respiratory infections. These viruses can infect animals as well ( 1 , 2 ). Up until the year 2003, coronavirus (CoV) had attracted limited interest from researchers. However, after the SARS (severe acute respiratory syndrome) outbreak caused by the SARS-CoV, the coronavirus was looked at with renewed interest ( 3 , 4 ). This also happened to be the first epidemic of the 21st century originating in the Guangdong province of China. Almost 10 years later, there was a MERS (Middle East respiratory syndrome) outbreak in 2012, which was caused by the MERS-CoV ( 5 , 6 ). Both SARS and MERS have a zoonotic origin and originated from bats. A unique feature of these viruses is the ability to mutate rapidly and adapt to a new host. The zoonotic origin of these viruses allows them to jump from host to host. Coronaviruses are known to use the angiotensin-converting enzyme-2 (ACE-2) receptor or the dipeptidyl peptidase IV (DPP-4) protein to gain entry into cells for replication ( 7 – 10 ).

In December 2019, almost seven years after the MERS 2012 outbreak, a novel Coronavirus (2019-nCoV) surfaced in Wuhan in the Hubei region of China. The outbreak rapidly grew and spread to neighboring countries. However, rapid communication of information and the increasing scale of events led to quick quarantine and screening of travelers, thus containing the spread of the infection. The major part of the infection was restricted to China, and a second cluster was found on a cruise ship called the Diamond Princess docked in Japan ( 11 , 12 ).

The new virus was identified to be a novel Coronavirus and was thus initially named 2019-nCoV; later, it was renamed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ( 13 ), and the disease it causes is now referred to as Coronavirus Disease-2019 (COVID-19) by the WHO. The virus was suspected to have begun its spread in the Huanan seafood wholesale market in the Wuhan region. It is possible that an animal that was carrying the virus was brought into or sold in the market, causing the spread of the virus in the crowded marketplace. One of the first claims made was in an article published in the Journal of Medical Virology ( 14 ), which identified snakes as the possible host. A second possibility was that pangolins could be the wild host of SARS-CoV-2 ( 15 ), though the most likely possibility is that the virus originated from bats ( 13 , 16 – 19 ). Increasing evidence and experts are now collectively concluding the virus had a natural origin in bats, as with previous such respiratory viruses ( 2 , 20 – 24 ).

Similarly, SARS and MERS were also suspected to originate from bats. In the case of MERS, the dromedary camel is an intermediate host ( 5 , 10 ). Bats have been known to harbor coronaviruses for quite some time now. Just as in the case of avian flu, SARS, MERS, and possibly even HIV, with increasing selection and ecological pressure due to human activities, the virus made the jump from animal to man. Humans have been encroaching increasingly into forests, and this is true over much of China, as in Africa. Combined with additional ecological pressure due to climate change, such zoonotic spillovers are now more common than ever. It is likely that the next disease X will also have such an origin ( 25 ). We have learned the importance of identification of the source organism due to the Ebola virus pandemic. Viruses are unstable organisms genetically, constantly mutating by genetic shift or drift. It is not possible to predict when a cross-species jump may occur and when a seemingly harmless variant form of the virus may turn into a deadly strain. Such an incident occurred in Reston, USA, with the Reston virus ( 26 ), an alarming reminder of this possibility. The identification of the original host helps us to contain future spreads as well as to learn about the mechanism of transmission of viruses. Until the virus is isolated from a wild animal host, in this case, mostly bats, the zoonotic origin will remain hypothetical, though likely. It should further be noted that the virus has acquired several mutations, as noted by a group in China, indicating that there are more than two strains of the virus, which may have had an impact on its pathogenicity. However, this claim remains unproven, and many experts have argued otherwise; data proving this are not yet available ( 27 ). A similar finding was reported from Italy and India independently, where they found two strains ( 28 , 29 ). These findings need to be further cross-verified by similar analyses globally. If true, this finding could effectively explain why some nations are more affected than others.

Transmission

When the spread of COVID-19 began ( Figure 1 ), the virus appeared to be contained within China and the cruise ship “Diamond Princess,” which formed the major clusters of the virus. However, as of April 2020, over 210 countries and territories are affected by the virus, with Europe, the USA, and Iran forming the new cluster of the virus. The USA ( Figure 2 ) has the highest number of confirmed COVID-19 cases, whereas India and China, despite being among the most population-dense countries in the world, have managed to constrain the infection rate by the implementation of a complete lockdown with arrangements in place to manage the confirmed cases. Similarly, the UK has also managed to maintain a low curve of the graph by implementing similar measures, though it was not strictly enforced. Reports have indicated that the presence of different strains or strands of the virus may have had an effect on the management of the infection rate of the virus ( 27 – 29 ). The disease is spread by droplet transmission. As of April 2020, the total number of infected individuals stands at around 3 million, with ~200,000 deaths and more than 1 million recoveries globally ( 30 , 34 ). The virus thus has a fatality rate of around 2% and an R 0 of 3 based on current data. However, a more recent report from the CDC, Atlanta, USA, claims that the R 0 could be as high as 5.7 ( 35 ). It has also been observed from data available from China and India that individuals likely to be infected by the virus from both these countries belong to the age groups of 20–50 years ( 36 , 37 ). In both of these countries, the working class mostly belongs to this age group, making exposure more likely. Germany and Singapore are great examples of countries with a high number of cases but low fatalities as compared to their immediate neighbors. Singapore is one of the few countries that had developed a detailed plan of action after the previous SARS outbreak to deal with a similar situation in the future, and this worked in their favor during this outbreak. Both countries took swift action after the outbreak began, with Singapore banning Chinese travelers and implementing screening and quarantine measures at a time when the WHO recommended none. They ordered the elderly and the vulnerable to strictly stay at home, and they ensured that lifesaving equipment and large-scale testing facilities were available immediately ( 38 , 39 ). Germany took similar measures by ramping up testing capacity quite early and by ensuring that all individuals had equal opportunity to get tested. This meant that young, old, and at-risk people all got tested, thus ensuring positive results early during disease progression and that most cases were mild like in Singapore, thus maintaining a lower death percentage ( 40 ). It allowed infected individuals to be identified and quarantined before they even had symptoms. Testing was carried out at multiple labs, reducing the load and providing massive scale, something which countries such as the USA did quite late and India restricted to select government and private labs. The German government also banned large gatherings and advocated social distancing to further reduce the spread, though unlike India and the USA, this was done quite late. South Korea is another example of how a nation has managed to contain the spread and transmission of the infection. South Korea and the USA both reported their first COVID-19 cases on the same day; however, the US administration downplayed the risks of the disease, unlike South Korean officials, who constantly informed their citizens about the developments of the disease using the media and a centralized messaging system. They also employed the Trace, Test, and Treat protocol to identify and isolate patients fast, whereas the USA restricted this to patients with severe infection and only later broadened this criterion, like many European countries as well as India. Unlike the USA, South Korea also has universal healthcare, ensuring free diagnostic testing.

Figure 1 . Timeline of COVID-19 progression ( 30 – 32 ).

Figure 2 . Total confirmed COVID 19 cases as of May 2020 ( 33 ).

The main mode of transmission of 2019-nCoV is human to human. As of now, animal-to-human transfer has not yet been confirmed. Asymptomatic carriers of the virus are at major risk of being superinfectors with this disease, as all those infected may not develop the disease ( 41 ). This is a concern that has been raised by nations globally, with the Indian government raising concerns on how to identify and contain asymptomatic carriers, who could account for 80% of those infected ( 42 ). Since current resources are directed towards understanding the hospitalized individuals showing symptoms, there is still a vast amount of information about asymptomatic individuals that has yet to be studied. For example, some questions that need to be answered include: Do asymptomatic individuals develop the disease at any point in time at all? Do they eventually develop antibodies? How long do they shed the virus for? Can any tissue of these individuals store the virus in a dormant state? Asymptomatic transmission is a gray area that encompasses major unknowns in COVID-19.

The main route of human-to-human transmission is by droplets, which are generated during coughing, talking, or sneezing and are then inhaled by a healthy individual. They can also be indirectly transmitted to a person when they land on surfaces that are touched by a healthy individual who may then touch their nose, mouth, or eyes, allowing the virus entry into the body. Fomites are also a common issue in such diseases ( 43 ).

Aerosol-based transmission of the virus has not yet been confirmed ( 43 ). Stool-based transmission via the fecal-oral route may also be possible since the SARS-CoV-2 has been found in patient feces ( 44 , 45 ). Some patients with COVID-19 tend to develop diarrhea, which can become a major route of transmission if proper sanitation and personal hygiene needs are not met. There is no evidence currently available to suggest intrauterine vertical transmission of the disease in pregnant women ( 46 ).

More investigation is necessary of whether climate has played any role in the containment of the infection in countries such as India, Singapore, China, and Israel, as these are significantly warmer countries as compared with the UK, the USA, and Canada ( Figure 2 ). Ideally, a warm climate should prevent the virus from surviving for longer periods of time on surfaces, reducing transmissibility.

Pathophysiology

On gaining entry via any of the mucus membranes, the single-stranded RNA-based virus enters the host cell using type 2 transmembrane serine protease (TMPRSS2) and ACE2 receptor protein, leading to fusion and endocytosis with the host cell ( 47 – 49 ). The uncoated RNA is then translated, and viral proteins are synthesized. With the help of RNA-dependant RNA polymerase, new RNA is produced for the new virions. The cell then undergoes lysis, releasing a load of new virions into the patients' body. The resultant infection causes a massive release of pro-inflammatory cytokines that causes a cytokine storm.

Clinical Presentation

The clinical presentation of the disease resembles beta coronavirus infections. The virus has an incubation time of 2–14 days, which is the reason why most patients suspected to have the illness or contact with an individual having the illness remain in quarantine for the said amount of time. Infection with SARS-CoV-2 causes severe pneumonia, intermittent fever, and cough ( 50 , 51 ). Symptoms of rhinorrhoea, pharyngitis, and sneezing have been less commonly seen. Patients often develop acute respiratory distress syndrome within 2 days of hospital admission, requiring ventilatory support. It has been observed that during this phase, the mortality tends to be high. Chest CT will show indicators of pneumonia and ground-glass opacity, a feature that has helped to improve the preliminary diagnosis ( 51 ). The primary method of diagnosis for SARS-CoV-2 is with the help of PCR. For the PCR testing, the US CDC recommends testing for the N gene, whereas the Chinese CDC recommends the use of ORF lab and N gene of the viral genome for testing. Some also rely on the radiological findings for preliminary screening ( 52 ). Additionally, immunodiagnostic tests based on the presence of antibodies can also play a role in testing. While the WHO recommends the use of these tests for research use, many countries have pre-emptively deployed the use of these tests in the hope of ramping up the rate and speed of testing ( 52 – 54 ). Later, they noticed variations among the results, causing them to stop the use of such kits; there was also debate among the experts about the sensitivity and specificity of the tests. For immunological tests, it is beneficial to test for antibodies against the virus produced by the body rather than to test for the presence of the viral proteins, since the antibodies can be present in larger titers for a longer span of time. However, the cross-reactivity of these tests with other coronavirus antibodies is something that needs verification. Biochemical parameters such as D-dimer, C-reactive protein, and variations in neutrophil and lymphocyte counts are some other parameters that can be used to make a preliminary diagnosis; however, these parameters vary in a number of diseases and thus cannot be relied upon conclusively ( 51 ). Patients with pre-existing diseases such as asthma or similar lung disorder are at higher risk, requiring life support, as are those with other diseases such as diabetes, hypertension, or obesity. Those above the age of 60 have displayed the highest mortality rate in China, a finding that is mirrored in other nations as well ( Figure 3 ) ( 55 ). If we cross-verify these findings with the population share that is above the age of 70, we find that Italy, the United Kingdom, Canada, and the USA have one of the highest elderly populations as compared to countries such as India and China ( Figure 4 ), and this also reflects the case fatality rates accordingly ( Figure 5 ) ( 33 ). This is a clear indicator that aside from comorbidities, age is also an independent risk factor for death in those infected by COVID-19. Also, in the US, it was seen that the rates of African American deaths were higher. This is probably due to the fact that the prevalence of hypertension and obesity in this community is higher than in Caucasians ( 56 , 57 ). In late April 2020, there are also claims in the US media that young patients in the US with COVID-19 may be at increased risk of stroke; however, this is yet to be proven. We know that coagulopathy is a feature of COVID-19, and thus stroke is likely in this condition ( 58 , 59 ). The main cause of death in COVID-19 patients was acute respiratory distress due to the inflammation in the linings of the lungs caused by the cytokine storm, which is seen in all non-survival cases and in respiratory failure. The resultant inflammation in the lungs, served as an entry point of further infection, associated with coagulopathy end-organ failure, septic shock, and secondary infections leading to death ( 60 – 63 ).

Figure 3 . Case fatality rate by age in selected countries as of April 2020 ( 33 ).

Figure 4 . Case fatality rate in selected countries ( 33 ).

Figure 5 . Population share above 70 years of age ( 33 ).

For COVID-19, there is no specific treatment available. The WHO announced the organization of a trial dubbed the “Solidarity” clinical trial for COVID-19 treatments ( 64 ). This is an international collaborative study that investigates the use of a few prime candidate drugs for use against COVID-19, which are discussed below. The study is designed to reduce the time taken for an RCT by over 80%. There are over 1087 studies ( Supplementary Data 1 ) for COVID-19 registered at clinicaltrials.gov , of which 657 are interventional studies ( Supplementary Data 2 ) ( 65 ). The primary focus of the interventional studies for COVID-19 has been on antimalarial drugs and antiviral agents ( Table 1 ), while over 200 studies deal with the use of different forms of oxygen therapy. Most trials focus on improvement of clinical status, reduction of viral load, time to improvement, and reduction of mortality rates. These studies cover both severe and mild cases.

Table 1 . List of therapeutic drugs under study for COVID-19 as per clinical trials registered under clinicaltrials.gov .

Use of Antimalarial Drugs Against SARS-CoV-2

The use of chloroquine for the treatment of corona virus-based infection has shown some benefit in the prevention of viral replication in the cases of SARS and MERS. However, it was not validated on a large scale in the form of a randomized control trial ( 50 , 66 – 68 ). The drugs of choice among antimalarials are Chloroquine (CQ) and Hydroxychloroquine (HCQ). The use of CQ for COVID-19 was brought to light by the Chinese, especially by the publication of a letter to the editor of Bioscience Trends by Gao et al. ( 69 ). The letter claimed that several studies found CQ to be effective against COVID-19; however, the letter did not provide many details. Immediately, over a short span of time, interest in these two agents grew globally. Early in vitro data have revealed that chloroquine can inhibit the viral replication ( 70 , 71 ).

HCQ and CQ work by raising the pH of the lysosome, the cellular organelle that is responsible for phagocytic degradation. Its function is to combine with cell contents that have been phagocytosed and break them down eventually, in some immune cells, as a downstream process to display some of the broken proteins as antigens, thus further enhancing the immune recruitment against an antigen/pathogen. The drug was to be administered alone or with azithromycin. The use of azithromycin may be advocated by the fact that it has been seen previously to have some immunomodulatory role in airway-related disease. It appears to reduce the release of pro-inflammatory cytokines in respiratory illnesses ( 72 ). However, HCQ and azithromycin are known to have a major drug interaction when co-administered, which increases the risk of QT interval prolongation ( 73 ). Quinine-based drugs are known to have adverse effects such as QT prolongation, retinal damage, hypoglycemia, and hemolysis of blood in patients with G-6-PD deficiency ( 66 ). Several preprints, including, a metanalysis now indicate that HCQ may have no benefit for severe or critically ill patients who have COVID-19 where the outcome is need for ventilation or death ( 74 , 75 ). As of April 21, 2020, after having pre-emptively recommended their use for SARS-CoV-2 infection, the US now advocates against the use of these two drugs based on the new data that has become available.

Use of Antiviral Drugs Against SARS-CoV-2

The antiviral agents are mainly those used in the case of HIV/AIDS, these being Lopinavir and Ritonavir. Other agents such as nucleoside analogs like Favipiravir, Ribavirin, Remdesivir, and Galidesivir have been tested for possible activity in the prevention of viral RNA synthesis ( 76 ). Among these drugs, Lopinavir, Ritonavir, and Remdesivir are listed in the Solidarity trial by the WHO.

Remdesivir is a nucleotide analog for adenosine that gets incorporated into the viral RNA, hindering its replication and causing chain termination. This agent was originally developed for Ebola Virus Disease ( 77 ). A study was conducted with rhesus macaques infected with SARS-CoV-2 ( 78 ). In that study, after 12 h of infection, the monkeys were treated with either Remdesivir or vehicle. The drug showed good distribution in the lungs, and the animals treated with the drug showed a better clinical score than the vehicle group. The radiological findings of the study also indicated that the animals treated with Remdesivir have less lung damage. There was a reduction in viral replication but not in virus shedding. Furthermore, there were no mutations found in the RNA polymerase sequences. A randomized clinical control study that became available in late April 2020 ( 79 ), having 158 on the Remdesivir arm and 79 on the placebo arm, found that Remdesivir reduced the time to recovery in the Remdesivir-treated arm to 11 days, while the placebo-arm recovery time was 15 days. Though this was not found to be statistically significant, the agent provided a basis for further studies. The 28-days mortality was found to be similar for both groups. This has now provided us with a basis on which to develop future molecules. The study has been supported by the National Institute of Health, USA. The authors of the study advocated for more clinical trials with Remdesivir with a larger population. Such larger studies are already in progress, and their results are awaited. Remdesivir is currently one of the drugs that hold most promise against COVID-19.

An early trial in China with Lopinavir and Ritonavir showed no benefit compared with standard clinical care ( 80 ). More studies with this drug are currently underway, including one in India ( 81 , 82 ).

Use of Convalescent Patient Plasma

Another possible option would be the use of serum from convalescent individuals, as this is known to contain antibodies that can neutralize the virus and aid in its elimination. This has been tried previously for other coronavirus infections ( 83 ). Early emerging case reports in this aspect look promising compared to other therapies that have been tried ( 84 – 87 ). A report from China indicates that five patients treated with plasma recovered and were eventually weaned off ventilators ( 84 ). They exhibited reductions in fever and viral load and improved oxygenation. The virus was not detected in the patients after 12 days of plasma transfusion. The US FDA has provided detailed recommendations for investigational COVID-19 Convalescent Plasma use ( 88 ). One of the benefits of this approach is that it can also be used for post-exposure prophylaxis. This approach is now beginning to be increasingly adopted in other countries, with over 95 trials registered on clinicaltrials.gov alone, of which at least 75 are interventional ( 89 ). The use of convalescent patient plasma, though mostly for research purposes, appears to be the best and, so far, the only successful option for treatment available.

From a future perspective, the use of monoclonal antibodies for the inhibition of the attachment of the virus to the ACE-2 receptor may be the best bet. Aside from this, ACE-2-like molecules could also be utilized to attach and inactivate the viral proteins, since inhibition of the ACE-2 receptor would not be advisable due to its negative repercussions physiologically. In the absence of drug regimens and a vaccine, the treatment is symptomatic and involves the use of non-invasive ventilation or intubation where necessary for respiratory failure patients. Patients that may go into septic shock should be managed as per existing guidelines with hemodynamic support as well as antibiotics where necessary.

The WHO has recommended that simple personal hygiene practices can be sufficient for the prevention of spread and containment of the disease ( 90 ). Practices such as frequent washing of soiled hands or the use of sanitizer for unsoiled hands help reduce transmission. Covering of mouth while sneezing and coughing, and disinfection of surfaces that are frequently touched, such as tabletops, doorknobs, and switches with 70% isopropyl alcohol or other disinfectants are broadly recommended. It is recommended that all individuals afflicted by the disease, as well as those caring for the infected, wear a mask to avoid transmission. Healthcare works are advised to wear a complete set of personal protective equipment as per WHO-provided guidelines. Fumigation of dormitories, quarantine rooms, and washing of clothes and other fomites with detergent and warm water can help get rid of the virus. Parcels and goods are not known to transmit the virus, as per information provided by the WHO, since the virus is not able to survive sufficiently in an open, exposed environment. Quarantine of infected individuals and those who have come into contact with an infected individual is necessary to further prevent transmission of the virus ( 91 ). Quarantine is an age-old archaic practice that continues to hold relevance even today for disease containment. With the quarantine being implemented on such a large scale in some countries, taking the form of a national lockdown, the question arises of its impact on the mental health of all individuals. This topic needs to be addressed, especially in countries such as India and China, where it is still a matter of partial taboo to talk about it openly within the society.

In India, the Ministry of Ayurveda, Yoga, and Naturopathy, Unani, Siddha and Homeopathy (AYUSH), which deals with the alternative forms of medicine, issued a press release that the homeopathic, drug Arsenicum album 30, can be taken on an empty stomach for 3 days to provide protection against the infection ( 92 ). It also provided a list of herbal drugs in the same press release as per Ayurvedic and Unani systems of medicine that can boost the immune system to deal with the virus. However, there is currently no evidence to support the use of these systems of medicine against COVID-19, and they need to be tested.

The prevention of the disease with the use of a vaccine would provide a more viable solution. There are no vaccines available for any of the coronaviruses, which includes SARS and MERS. The development of a vaccine, however, is in progress at a rapid pace, though it could take about a year or two. As of April 2020, no vaccine has completed the development and testing process. A popular approach has been with the use of mRNA-based vaccine ( 93 – 96 ). mRNA vaccines have the advantage over conventional vaccines in terms of production, since they can be manufactured easily and do not have to be cultured, as a virus would need to be. Alternative conventional approaches to making a vaccine against SARS-CoV-2 would include the use of live attenuated virus as well as using the isolated spike proteins of the virus. Both of these approaches are in progress for vaccine development ( 97 ). Governments across the world have poured in resources and made changes in their legislation to ensure rapid development, testing, and deployment of a vaccine.

Barriers to Treatment

Lack of transparency and poor media relations.

The lack of government transparency and poor reporting by the media have hampered the measures that could have been taken by healthcare systems globally to deal with the COVID-19 threat. The CDC, as well as the US administration, downplayed the threat and thus failed to stock up on essential supplies, ventilators, and test kits. An early warning system, if implemented, would have caused borders to be shut and early lockdowns. The WHO also delayed its response in sounding the alarm regarding the severity of the outbreak to allow nations globally to prepare for a pandemic. Singapore is a prime example where, despite the WHO not raising concerns and banning travel to and from China, a country banned travelers and took early measures, thus managing the outbreak quite well. South Korea is another example of how things may have played out had those measures by agencies been taken with transparency. Increased transparency would have allowed the healthcare sector to better prepare and reduced the load of patients they had to deal with, helping flatten the curve. The increased patient load and confusion among citizens arising from not following these practices has proved to be a barrier to providing effective treatments to patients with the disease elsewhere in the world.

Lack of Preparedness and Protocols

Despite the previous SARS outbreak teaching us important lessons and providing us with data on a potential outbreak, many nations did not take the important measures needed for a future outbreak. There was no allocation of sufficient funds for such an event. Many countries experienced severe lack of PPE, and the lockdown precautions hampered the logistics of supply and manufacturing of such essential equipment. Singapore and South Korea had protocols in place and were able to implement them at a moment's notice. The spurt of cases that Korea experienced was managed well, providing evidence to this effect. The lack of preparedness and lack of protocol in other nations has resulted in confusion as to how the treatment may be administered safely to the large volume of patients while dealing with diagnostics. Both of these factors have limited the accessibility to healthcare services due to sheer volume.

Socio-Economic Impact

During the SARS epidemic, China faced an economic setback, and experts were unsure if any recovery would be made. However, the global and domestic situation was then in China's favor, as it had a lower debt, allowing it to make a speedy recovery. This is not the case now. Global experts have a pessimistic outlook on the outcome of this outbreak ( 98 ). The fear of COVID-19 disease, lack of proper understanding of the dangers of the virus, and the misinformation spread on the social media ( 99 ) have caused a breakdown of the economic flow globally ( 100 ). An example of this is Indonesia, where a great amount of fear was expressed in responses to a survey when the nation was still free of COVID-19 ( 101 ). The pandemic has resulted in over 2.6 billion people being put under lockdown. This lockdown and the cancellation of the lunar year celebration has affected business at the local level. Hundreds of flights have been canceled, and tourism globally has been affected. Japan and Indonesia are estimated to lose over 2.44 billion dollars due to this ( 102 , 103 ). Workers are not able to work in factories, transportation in all forms is restricted, and goods are not produced or moved. The transport of finished products and raw materials out of China is low. The Economist has published US stock market details indicating that companies in the US that have Chinese roots fell, on average, 5 points on the stock market as compared to the S&P 500 index ( 104 ). Companies such as Starbucks have had to close over 4,000 outlets due to the outbreak as a precaution. Tech and pharma companies are at higher risk since they rely on China for the supply of raw materials and active pharmaceutical ingredients. Paracetamol, for one, has reported a price increase of over 40% in India ( 104 – 106 ). Mass hysteria in the market has caused selling of shares of these companies, causing a tumble in the Indian stock market. Though long-term investors will not be significantly affected, short-term traders will find themselves in soup. Politically, however, this has further bolstered support for world leaders in countries such as India, Germany, and the UK, who are achieving good approval ratings, with citizens being satisfied with the government's approach. In contrast, the ratings of US President Donald Trump have dropped due to the manner in which the COVID-19 pandemic was handled. These minor impacts may be of temporary significance, and the worst and direct impact will be on China itself ( 107 – 109 ), as the looming trade war with the USA had a negative impact on the Chinese and Asian markets. The longer production of goods continues to remain suspended, the more adversely it will affect the Chinese economy and the global markets dependent on it ( 110 ). If this disease is not contained, more and more lockdowns by multiple nations will severely affect the economy and lead to many social complications.

The appearance of the 2019 Novel Coronavirus has added and will continue to add to our understanding of viruses. The pandemic has once again tested the world's preparedness for dealing with such outbreaks. It has provided an outlook on how a massive-scale biological event can cause a socio-economic disturbance through misinformation and social media. In the coming months and years, we can expect to gain further insights into SARS-CoV-2 and COVID-19.

Author Contributions

KN: conceptualization. RK, AA, JM, and KN: investigation. RK and AA: writing—original draft preparation. KN, PN, and JM: writing—review and editing. KN: supervision.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to acknowledge the contributions made by Dr. Piya Paul Mudgal, Assistant Professor, Manipal Institute of Virology, Manipal Academy of Higher Education towards inputs provided by her during the drafting of the manuscript.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2020.00216/full#supplementary-material

Supplementary Data 1, 2. List of all studies registered for COVID-19 on clinicaltrials.gov .

1. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA. (1967) 57:933–40. doi: 10.1073/pnas.57.4.933

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis. (2005) 191:492–8. doi: 10.1086/428138

3. Stöhr K. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet. (2003) 361:1730–3. doi: 10.1016/S0140-6736(03)13376-4

4. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. (2003) 361:1319–25. doi: 10.1016/S0140-6736(03)13077-2

5. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. (2015) 386:995–1007. doi: 10.1016/S0140-6736(15)60454-8

6. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. (2012) 367:1814–20. doi: 10.1056/NEJMoa1211721

7. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. (2009) 7:439–50. doi: 10.1038/nrmicro2147

8. Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. (2003) 426:450–4. doi: 10.1038/nature02145

9. Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. (2013) 503:535–8. doi: 10.1038/nature12711

10. Wang M, Hu Z. Bats as animal reservoirs for the SARS coronavirus: Hypothesis proved after 10 years of virus hunting. Virol Sin. (2013) 28:315–7. doi: 10.1007/s12250-013-3402-x

11. Diamond Princess Cruise Ship in Japan Confirms 99 New Coronavirus Cases | World news | The Guardian. Available online at: https://www.theguardian.com/world/2020/feb/17/coronavirus-japan-braces-for-hundreds-more-cases-as-another-china-city-locked-down (accessed February 17, 2020).

Google Scholar

12. Diamond Princess Coronavirus & Quarantine Updates - Notices & Advisories - Princess Cruises. Available online at: https://www.princess.com/news/notices_and_advisories/notices/diamond-princess-update.html (accessed February 17, 2020).

13. Gorbalenya AE, Baker SC, Baric RS, Groot RJ, de Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:536–44. doi: 10.1038/s41564-020-0695-z

14. Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol . (2020) 7:jmv.25682. doi: 10.1002/jmv.25682

15. Cyranoski D. Did pangolins spread the China coronavirus to people? Nature . (2020) doi: 10.1038/d41586-020-00364-2

CrossRef Full Text | Google Scholar

16. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. (2020) 395:565–74. doi: 10.1016/S0140-6736(20)30251-8

17. Wassenaar TM, Zou Y. 2019_nCoV: Rapid classification of betacoronaviruses and identification of traditional Chinese medicine as potential origin of zoonotic coronaviruses. Lett Appl Microbiol. (2020) 70:324–48. doi: 10.1111/lam.13285

18. Velavan TP, Meyer CG. The Covid-19 epidemic. Trop Med Int Heal . (2020) 25:278–80. doi: 10.1111/tmi.13383

19. Guarner J. Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol . (2020) 153:420–21. doi: 10.1093/ajcp/aqaa029

20. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. (2005) 310:676–9. doi: 10.1126/science.1118391

21. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. doi: 10.1038/s41586-020-2012-7

22. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. (2015) 21:1508–13. doi: 10.1038/nm.3985

23. COVID-19 Coronavirus Epidemic has a Natural Origin—ScienceDaily. Available online at: https://www.sciencedaily.com/releases/2020/03/200317175442.htm (accessed April 22, 2020).

24. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med . (2020) 26:450–2. doi: 10.1038/s41591-020-0820-9

25. Prioritizing Diseases for Research and Development in Emergency Contexts. Available online at: https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts (accessed April 22, 2020).

26. Albariño CG, Guerrero LW, Jenks HM, Chakrabarti AK, Ksiazek TG, Rollin PE, et al. Insights into Reston virus spillovers and adaption from virus whole genome sequences. PLoS ONE. (2017) 12:e0178224. doi: 10.1371/journal.pone.0178224

27. Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng L, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv. (2020). doi: 10.2139/ssrn.3578153

28. Stefanelli P, Faggioni G, Lo Presti A, Fiore S, Marchi A, Benedetti E, et al. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Eurosurveillance. (2020) 25:2000305. doi: 10.2807/1560-7917.ES.2020.25.13.2000305

29. Yadav P, Potdar V, Choudhary M, Nyayanit D, Agrawal M, Jadhav S, et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. (2020) 151:200–9. doi: 10.4103/ijmr.IJMR_663_20

30. WHO | Coronavirus disease 2019 (COVID-19) Situation Report – 26. Beijing (2020). Available online at: http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml (accessed February 16, 2020).

31. WHO | Middle East Respiratory Syndrome Coronavirus (MERS-CoV). World Health Organization (2020).

32. WHO | Summary of Probable SARS Cases With Onset of Illness From 1 November 2002 to 31 July 2003. World Health Organization (2015).

33. Worldometer. Coronavirus cases. Worldometer. (2020) 1−22.

34. Update on the Outbreak of New Coronavirus Pneumonia as of 24 hours on 15 February. Beijing (2020). Available online at: http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml (accessed February 16, 2020).

35. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. (2020) 26. doi: 10.3201/eid2607.200282

36. 83% of India's Coronavirus Patients Are Below the Age of 50: Health ministry data - India News. Available online at: https://www.indiatoday.in/india/story/83-of-india-s-coronavirus-patients-are-below-the-age-of-50-health-ministry-data-1663314-2020-04-04 (accessed April 23, 2020).

37. 42% of Coronavirus Patients in 21-40 age bracket: Govt. Available online at: https://economictimes.indiatimes.com/news/politics-and-nation/42-of-coronavirus-patients-in-21-40-age-bracket-govt/articleshow/74987254.cms (accessed April 23, 2020).

38. Why COVID-19 Case Counts Are so Low in Singapore Hong Kong and Taiwan | Advisory Board Daily Briefing. Available online at: https://www.advisory.com/daily-briefing/2020/03/19/asian-countries (accessed April 29, 2020).

39. Coronavirus: Why so Few Deaths Among Singapore's 14000 Covid-19 Infections? | South China Morning Post. Available online at: https://www.scmp.com/weekasia/health-environment/article/3081772/coronavirus-why-so-few-deaths-among-singapores-14000 (accessed April 29, 2020).

40. Stafford N. Covid-19: Why Germany's case fatality rate seems so low. BMJ. (2020) 7:369. doi: 10.1136/bmj.m1395

41. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med . (2020) 382:970–1. doi: 10.1056/NEJMc2001468

42. Coronavirus pandemic | 80% of COVID-19 Cases Either Asymptomatic or Show Mild Symptoms. Health ministry - Moneycontrol.com. Available online at: https://www.moneycontrol.com/news/india/coronavirus-pandemic-80-of-covid-19-cases-either-asymptomatic-or-show-mild-symptoms-health-ministry-5170631.html (accessed April 24, 2020).

43. WHO | Q&A on Coronaviruses. Available online at: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses (accessed February 16, 2020).

44. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med . (2020) 382:929–36. doi: 10.1056/NEJMoa2001191

45. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. (2020) 5:335–37. doi: 10.1016/S2468-1253(20)30048-0

46. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. (2020) 395:809–15. doi: 10.1016/S0140-6736(20)30360-3

47. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. In: Coronaviruses: Methods and Protocols (New York: Springer), 1–23. doi: 10.1007/978-1-4939-2438-7_1

48. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. (2020) 92:418–23. doi: 10.1002/jmv.25681

49. Hoffmann M, Kleine-Weber H, Schroeder S, Mü MA, Drosten C, Pö S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80. doi: 10.1016/j.cell.2020.02.052

50. Cheng VCC, Chan JFW, To KKW, Yuen KY. Clinical management and infection control of SARS: Lessons learned. Antiviral Res. (2013) 100:407–19. doi: 10.1016/j.antiviral.2013.08.016

51. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

52. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano . (2020) 14:3822–35. doi: 10.1021/acsnano.0c02624

53. Testing, | CDC,. Available online at: https://www.cdc.gov/coronavirus/2019-ncov/testing/index.html (accessed April 29, 2020).

54. Advice on the Use of Point-of-Care Immunodiagnostic Tests for COVID-19. Available online at: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19 (accessed April 29, 2020).

55. Zhang Yanping. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. (2020) Available online at: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9bfea8db1a8f51 (accessed February 18, 2020).

56. Petersen R, Pan L, Blanck HM. Racial and ethnic disparities in adult obesity in the United States: CDC's tracking to inform state and local action. Prev Chronic Dis. (2019) 16:180579. doi: 10.5888/pcd16.180579

57. Wang L, Southerland J, Wang K, Bailey BA, Alamian A, Stevens MA, et al. Ethnic differences in risk factors for obesity among adults in California, the United States. (2017) 2017:2427483. doi: 10.1155/2017/2427483

58. Covid-19 Causes Sudden Strokes in Young Adults Doctors Say - CNN. Available online at: https://edition.cnn.com/2020/04/22/health/strokes-coronavirus-young-adults/index.html (accessed April 24, 2020).

59. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost . (2020) 1–4. doi: 10.1111/jth.14828

60. Lancet T, Medicine R. Comment Understanding pathways to death in patients with. Lancet Respir Med. (2020) 2019:2019–21. doi: 10.1016/S2213-2600(20)30165-X

61. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA . (2020) 323:1775–6. doi: 10.1001/jama.2020.4683

62. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3

63. Doctors Warn COVID-19 Might Cause Strokes in Young Adults. Available online at: https://nypost.com/2020/04/23/doctors-warn-covid-19-might-cause-strokes-in-young-adults/ (accessed April 24, 2020).

64. “Solidarity” Clinical Trial for COVID-19 Treatments. Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (accessed April 23, 2020).

65. Search, of: COVID-19 - List Results - ClinicalTrials.gov . Available online at: https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&cntry=&state=&city=&dist= (accessed May 1, 2020).

66. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. (2014) 58:4875–84. doi: 10.1128/AAC.03011-14

67. Tai DYH. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. (2007) 36:438–43.

PubMed Abstract | Google Scholar

68. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. (2020) 11:222. doi: 10.1038/s41467-019-13940-6

69. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. (2020) 14:72–73. doi: 10.5582/bst.2020.01047

70. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. doi: 10.1038/s41422-020-0282-0

71. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. (2005) 2:1–0. doi: 10.1186/1743-422X-2-69

72. Cramer CL, Patterson A, Alchakaki A, Soubani AO. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med. (2017) 129:493–9. doi: 10.1080/00325481.2017.1285677

73. Plaquenil™ Hydroxychloroquine Sulfate Tablets USP Description. Available online at: http://www.cdc.gov/malaria (accessed April 21, 2020).

74. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. (2020) doi: 10.1101/2020.04.16.20065920

75. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Ghasemian R, et al. Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis. medRxiv. (2020) doi: 10.1101/2020.04.14.20065276

76. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov . (2020) 19:149–50. doi: 10.1038/d41573-020-00016-0

77. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. (2016) 531:381–5. doi: 10.1038/nature17180

78. Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv. (2020) doi: 10.1101/2020.04.15.043166

79. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. doi: 10.1016/S0140-6736(20)31022-9

80. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med . (2020) 382:1787–99. doi: 10.1056/NEJMoa2001282

81. Search, of: Lopinavir, Ritonavir, | COVID - List Results - ClinicalTrials.gov . Available online at: https://clinicaltrials.gov/ct2/results?term=Lopinavir%2CRitonavir&cond=COVID&draw=4&rank=22#rowId21 (accessed April 23, 2020).

82. Bhatnagar T, Murhekar M, Soneja M, Gupta N, Giri S, Wig N, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. (2020) 151:184–9. doi: 10.4103/ijmr.IJMR_502_20

83. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. (2005) 56:919–22. doi: 10.1093/jac/dki346

84. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA . (2020) 323:1582–9. doi: 10.1001/jama.2020.4783

85. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis . (2020) 7:1–6. doi: 10.1093/ofid/ofaa102

86. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest . (2020) 138745:1–22. doi: 10.1172/JCI138745

87. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. (2 020) doi: 10.1002/jmv.25882

88. Recommendations for Investigational COVID-19 Convalescent Plasma | FDA. Available online at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (accessed April 23, 2020).

89. Search, of: plasma | Interventional Studies | COVID - List Results - ClinicalTrials.gov . Available online at: https://clinicaltrials.gov/ct2/results?term=plasma&cond=COVID&Search=Apply&age_v=&gndr=&type=Intr&rslt= (accessed April 23, 2020).

90. Infection Prevention and Control. Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control (accessed February 17, 2020).

91. Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med . (2020) 27:taaa020. doi: 10.1093/jtm/taaa020

92. Press Information Bureau AYUSH Advisory for Corona virus. Press Inf Bereau. Available online at: https://pib.gov.in/PressReleasePage.aspx?PRID=1600895 (accessed February 17, 2020).

93. CanSino, Biologics : China Announces First Human Trials of Covid-19 Vaccine | MarketScreener,. Available online at: https://www.marketscreener.com/CANSINO-BIOLOGICS-INC-59318312/news/CanSino-Biologics-China-announces-first-human-trials-of-Covid-19-vaccine-30183232/ (accessed April 7, 2020).

94. Safety, and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection - Full Text View - ClinicalTrials.gov . Available online at: https://clinicaltrials.gov/ct2/show/NCT04283461 (accessed April 7, 2020).

95. NIH, Clinical Trial of Investigational Vaccine for COVID-19 Begins | National Institutes of Health (NIH),. Available at: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins (accessed April 7, 2020).

96. Novel, Coronavirus vaccine manufacturing contract signed — The Jenner Institute,. Available online at: https://www.jenner.ac.uk/about/news/novel-coronavirus-vaccine-manufacturing-contract-signed (accessed April 7, 2020).

97. Xie L, Sun C, Luo C, Zhang Y, Zhang J, Yang J, et al. SARS-CoV-2 and SARS-CoV Spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development. bioRxiv [Preprint]. (2020). doi: 10.1101/2020.02.16.951723

98. The Global Economic Impact of the Coronavirus Outbreak – Harvard Gazette. Available online at: https://news.harvard.edu/gazette/story/2020/02/the-global-economic-impact-of-the-coronavirus-outbreak/ (accessed February 17, 2020).

99. Shimizu K. 2019-nCoV, fake news, and racism. Lancet . (2020) 395:685–6. doi: 10.1016/S0140-6736(20)30357-3

100. ROHDE RODNEY. 2019 Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus. Am Soc Microbiol. (2020). Available online at: https://asm.org/Articles/2020/January/2019-Novel-Coronavirus-2019-nCoV-Update-Uncoating

101. Virus-free Indonesia more threatened by COVID-19 than Singapore Malaysia: Survey - World - The Jakarta Post. Available online at: https://www.thejakartapost.com/news/2020/02/18/virus-free-indonesia-more-threatened-by-covid-19-than-singapore-malaysia-survey.html (accessed February 18, 2020).

102. Japan, May Lose $1,.29 Billion in Tourism Revenue Due to COVID-19 Outbreak | The Japan Times. Available online at: https://www.japantimes.co.jp/news/2020/02/16/business/economy-business/japan-lose-billion-tourism-revenue-covid19-outbreak/#.XkvxX0fitPY (accessed February 18, 2020).

103. Coronavirus's Effect on Tourism Will Carry Into 2021 Experts Say - Bloomberg. Available online at: https://www.bloomberg.com/news/articles/2020-02-13/coronavirus-s-effect-on-tourism-will-carry-into-2021-experts-say (accessed February 18, 2020).

104. The, week in charts - The cost of covid-19 | Graphic detail | The Economist,. Available online at: https://www.economist.com/graphic-detail/2020/02/14/the-cost-of-covid-19 (accessed February 17, 2020).

105. coronavirus: Covid-19 Impact: Pharma Companies Feel the Pain as Prices of Key Inputs Shoot Up - The Economic Times. Available online at: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-impact-pharma-companies-feel-the-pain-as-prices-of-key-inputs-shoot-up/articleshow/74144044.cms?from=mdr (accessed February 17, 2020).

106. Coronavirus Outbreak: Paracetamol Prices Jump 40% In India As Coronavirus Shuts Down China. Available online at: https://www.ndtv.com/india-news/coronavirus-outbreak-paracetamol-prices-jump-40-in-india-as-coronavirus-shuts-down-china-2181480 (accessed February 18, 2020).

107. The coronavirus could cripple China's economy for longer than Wall Street wants to believe | Business Insider India. Available online at: https://www.businessinsider.in/international/news/the-coronavirus-could-cripple-chinas-economy-for-longer-than-wall-street-wants-to-believe/articleshow/74162183.cms (accessed February 17, 2020).

108. Viral Slowdown - How China's Coronavirus Epidemic Could Hurt the World Economy | Leaders | The Economist. Available online at: https://www.economist.com/leaders/2020/02/13/how-chinas-coronavirus-epidemic-could-hurt-the-world-economy (accessed February 17, 2020).

109. China's Economic Battle With COVID-19 | The ASEAN Post. Available online at: https://theaseanpost.com/article/chinas-economic-battle-covid-19 (accessed February 17, 2020).

110. The Coronavirus Could Cost China's Economy $60 Billion this Quarter. - CNN. Available online at: https://edition.cnn.com/2020/01/31/economy/china-economy-coronavirus/index.html (accessed February 18, 2020).

Keywords: 2019-nCoV, COVID-19, SARS-CoV-2, coronavirus, pandemic, SARS

Citation: Keni R, Alexander A, Nayak PG, Mudgal J and Nandakumar K (2020) COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. Front. Public Health 8:216. doi: 10.3389/fpubh.2020.00216

Received: 21 February 2020; Accepted: 11 May 2020; Published: 28 May 2020.

Reviewed by:

Copyright © 2020 Keni, Alexander, Nayak, Mudgal and Nandakumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Krishnadas Nandakumar, mailnandakumar77@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

How to Write About Coronavirus in a College Essay

Students can share how they navigated life during the coronavirus pandemic in a full-length essay or an optional supplement.

Writing About COVID-19 in College Essays

Serious disabled woman concentrating on her work she sitting at her workplace and working on computer at office

Getty Images

Experts say students should be honest and not limit themselves to merely their experiences with the pandemic.

The global impact of COVID-19, the disease caused by the novel coronavirus, means colleges and prospective students alike are in for an admissions cycle like no other. Both face unprecedented challenges and questions as they grapple with their respective futures amid the ongoing fallout of the pandemic.

Colleges must examine applicants without the aid of standardized test scores for many – a factor that prompted many schools to go test-optional for now . Even grades, a significant component of a college application, may be hard to interpret with some high schools adopting pass-fail classes last spring due to the pandemic. Major college admissions factors are suddenly skewed.

"I can't help but think other (admissions) factors are going to matter more," says Ethan Sawyer, founder of the College Essay Guy, a website that offers free and paid essay-writing resources.

College essays and letters of recommendation , Sawyer says, are likely to carry more weight than ever in this admissions cycle. And many essays will likely focus on how the pandemic shaped students' lives throughout an often tumultuous 2020.

But before writing a college essay focused on the coronavirus, students should explore whether it's the best topic for them.

Writing About COVID-19 for a College Application

Much of daily life has been colored by the coronavirus. Virtual learning is the norm at many colleges and high schools, many extracurriculars have vanished and social lives have stalled for students complying with measures to stop the spread of COVID-19.

"For some young people, the pandemic took away what they envisioned as their senior year," says Robert Alexander, dean of admissions, financial aid and enrollment management at the University of Rochester in New York. "Maybe that's a spot on a varsity athletic team or the lead role in the fall play. And it's OK for them to mourn what should have been and what they feel like they lost, but more important is how are they making the most of the opportunities they do have?"

That question, Alexander says, is what colleges want answered if students choose to address COVID-19 in their college essay.

But the question of whether a student should write about the coronavirus is tricky. The answer depends largely on the student.

"In general, I don't think students should write about COVID-19 in their main personal statement for their application," Robin Miller, master college admissions counselor at IvyWise, a college counseling company, wrote in an email.

"Certainly, there may be exceptions to this based on a student's individual experience, but since the personal essay is the main place in the application where the student can really allow their voice to be heard and share insight into who they are as an individual, there are likely many other topics they can choose to write about that are more distinctive and unique than COVID-19," Miller says.

Opinions among admissions experts vary on whether to write about the likely popular topic of the pandemic.

"If your essay communicates something positive, unique, and compelling about you in an interesting and eloquent way, go for it," Carolyn Pippen, principal college admissions counselor at IvyWise, wrote in an email. She adds that students shouldn't be dissuaded from writing about a topic merely because it's common, noting that "topics are bound to repeat, no matter how hard we try to avoid it."

Above all, she urges honesty.

"If your experience within the context of the pandemic has been truly unique, then write about that experience, and the standing out will take care of itself," Pippen says. "If your experience has been generally the same as most other students in your context, then trying to find a unique angle can easily cross the line into exploiting a tragedy, or at least appearing as though you have."

But focusing entirely on the pandemic can limit a student to a single story and narrow who they are in an application, Sawyer says. "There are so many wonderful possibilities for what you can say about yourself outside of your experience within the pandemic."

He notes that passions, strengths, career interests and personal identity are among the multitude of essay topic options available to applicants and encourages them to probe their values to help determine the topic that matters most to them – and write about it.

That doesn't mean the pandemic experience has to be ignored if applicants feel the need to write about it.

Writing About Coronavirus in Main and Supplemental Essays

Students can choose to write a full-length college essay on the coronavirus or summarize their experience in a shorter form.

To help students explain how the pandemic affected them, The Common App has added an optional section to address this topic. Applicants have 250 words to describe their pandemic experience and the personal and academic impact of COVID-19.

"That's not a trick question, and there's no right or wrong answer," Alexander says. Colleges want to know, he adds, how students navigated the pandemic, how they prioritized their time, what responsibilities they took on and what they learned along the way.

If students can distill all of the above information into 250 words, there's likely no need to write about it in a full-length college essay, experts say. And applicants whose lives were not heavily altered by the pandemic may even choose to skip the optional COVID-19 question.

"This space is best used to discuss hardship and/or significant challenges that the student and/or the student's family experienced as a result of COVID-19 and how they have responded to those difficulties," Miller notes. Using the section to acknowledge a lack of impact, she adds, "could be perceived as trite and lacking insight, despite the good intentions of the applicant."

To guard against this lack of awareness, Sawyer encourages students to tap someone they trust to review their writing , whether it's the 250-word Common App response or the full-length essay.

Experts tend to agree that the short-form approach to this as an essay topic works better, but there are exceptions. And if a student does have a coronavirus story that he or she feels must be told, Alexander encourages the writer to be authentic in the essay.

"My advice for an essay about COVID-19 is the same as my advice about an essay for any topic – and that is, don't write what you think we want to read or hear," Alexander says. "Write what really changed you and that story that now is yours and yours alone to tell."

Sawyer urges students to ask themselves, "What's the sentence that only I can write?" He also encourages students to remember that the pandemic is only a chapter of their lives and not the whole book.

Miller, who cautions against writing a full-length essay on the coronavirus, says that if students choose to do so they should have a conversation with their high school counselor about whether that's the right move. And if students choose to proceed with COVID-19 as a topic, she says they need to be clear, detailed and insightful about what they learned and how they adapted along the way.

"Approaching the essay in this manner will provide important balance while demonstrating personal growth and vulnerability," Miller says.

Pippen encourages students to remember that they are in an unprecedented time for college admissions.

"It is important to keep in mind with all of these (admission) factors that no colleges have ever had to consider them this way in the selection process, if at all," Pippen says. "They have had very little time to calibrate their evaluations of different application components within their offices, let alone across institutions. This means that colleges will all be handling the admissions process a little bit differently, and their approaches may even evolve over the course of the admissions cycle."

Searching for a college? Get our complete rankings of Best Colleges.

10 Ways to Discover College Essay Ideas

Tags: students , colleges , college admissions , college applications , college search , Coronavirus

2024 Best Colleges

Search for your perfect fit with the U.S. News rankings of colleges and universities.

College Admissions: Get a Step Ahead!

Sign up to receive the latest updates from U.S. News & World Report and our trusted partners and sponsors. By clicking submit, you are agreeing to our Terms and Conditions & Privacy Policy .

Ask an Alum: Making the Most Out of College

How to Win a Fulbright Scholarship

Cole Claybourn and Ilana Kowarski April 26, 2024

Honors Colleges and Programs

Sarah Wood April 26, 2024

Find a Job in the Age of AI

Angie Kamath April 25, 2024

Protests Boil Over on College Campuses

Lauren Camera April 22, 2024

Supporting Low-Income College Applicants

Shavar Jeffries April 16, 2024

Supporting Black Women in Higher Ed

Zainab Okolo April 15, 2024

Law Schools With the Highest LSATs

Ilana Kowarski and Cole Claybourn April 11, 2024

Today NAIA, Tomorrow Title IX?

Lauren Camera April 9, 2024

Grad School Housing Options

Anayat Durrani April 9, 2024

Persuasive Essay Guide

Persuasive Essay About Covid19

How to Write a Persuasive Essay About Covid19 | Examples & Tips

11 min read

Steps to Write a Persuasive Essay About Covid-19

Here are the steps to help you write a persuasive essay on this topic, along with an example essay:

Step 1: Choose a Specific Thesis Statement

Your thesis statement should clearly state your position on a specific aspect of COVID-19. It should be debatable and clear. For example:

Step 2: Research and Gather Information

Collect reliable and up-to-date information from reputable sources to support your thesis statement. This may include statistics, expert opinions, and scientific studies. For instance:

COVID-19 vaccination effectiveness data
Information on vaccine mandates in different countries
Expert statements from health organizations like the WHO or CDC

Step 3: Outline Your Essay

Create a clear and organized outline to structure your essay. A persuasive essay typically follows this structure:

Introduction
Background Information
Body Paragraphs (with supporting evidence)
Counterarguments (addressing opposing views)

Step 4: Write the Introduction

In the introduction, grab your reader's attention and present your thesis statement. For example:

Step 5: Provide Background Information

Offer context and background information to help your readers understand the issue better. For instance:

Step 6: Develop Body Paragraphs

Each body paragraph should present a single point or piece of evidence that supports your thesis statement. Use clear topic sentences, evidence, and analysis. Here's an example:

Step 7: Address Counterarguments

Acknowledge opposing viewpoints and refute them with strong counterarguments. This demonstrates that you've considered different perspectives. For example:

Step 8: Write the Conclusion

Summarize your main points and restate your thesis statement in the conclusion. End with a strong call to action or thought-provoking statement. For instance:

Step 9: Revise and Proofread

Edit your essay for clarity, coherence, grammar, and spelling errors. Ensure that your argument flows logically.

Step 10: Cite Your Sources

Include proper citations and a bibliography page to give credit to your sources.

Remember to adjust your approach and arguments based on your target audience and the specific angle you want to take in your persuasive essay about COVID-19.

Paper Due? Why Suffer? That's our Job!

Examples of Persuasive Essay About Covid19

When writing a persuasive essay about the Covid-19 pandemic, it’s important to consider how you want to present your argument. To help you get started, here are some example essays for you to read:

Check out some more PDF examples below:

Persuasive Essay About Covid-19 Pandemic

Sample Of Persuasive Essay About Covid-19

Persuasive Essay About Covid-19 In The Philippines - Example

If you're in search of a compelling persuasive essay on business, don't miss out on our “ persuasive essay about business ” blog!

Examples of Persuasive Essay About Covid-19 Vaccine

Covid19 vaccines are one of the ways to prevent the spread of Covid-19, but they have been a source of controversy. Different sides argue about the benefits or dangers of the new vaccines. Whatever your point of view is, writing a persuasive essay about it is a good way of organizing your thoughts and persuading others.

A persuasive essay about the Covid-19 vaccine could consider the benefits of getting vaccinated as well as the potential side effects.

Below are some examples of persuasive essays on getting vaccinated for Covid-19.

Covid19 Vaccine Persuasive Essay

Persuasive Essay on Covid Vaccines

Interested in thought-provoking discussions on abortion? Read our persuasive essay about abortion blog to eplore arguments!

Examples of Persuasive Essay About Covid-19 Integration

Covid19 has drastically changed the way people interact in schools, markets, and workplaces. In short, it has affected all aspects of life. However, people have started to learn to live with Covid19.

Writing a persuasive essay about it shouldn't be stressful. Read the sample essay below to get idea for your own essay about Covid19 integration.

Persuasive Essay About Working From Home During Covid19

Searching for the topic of Online Education? Our persuasive essay about online education is a must-read.

Examples of Argumentative Essay About Covid 19

Covid-19 has been an ever-evolving issue, with new developments and discoveries being made on a daily basis.

Writing an argumentative essay about such an issue is both interesting and challenging. It allows you to evaluate different aspects of the pandemic, as well as consider potential solutions.

Here are some examples of argumentative essays on Covid19.

Argumentative Essay About Covid19 Sample

Argumentative Essay About Covid19 With Introduction Body and Conclusion

Looking for a persuasive take on the topic of smoking? You'll find it all related arguments in out Persuasive Essay About Smoking blog!

Examples of Persuasive Speeches About Covid-19

Do you need to prepare a speech about Covid19 and need examples? We have them for you!

Persuasive speeches about Covid-19 can provide the audience with valuable insights on how to best handle the pandemic. They can be used to advocate for specific changes in policies or simply raise awareness about the virus.

Check out some examples of persuasive speeches on Covid-19:

Persuasive Speech About Covid-19 Example

Persuasive Speech About Vaccine For Covid-19

You can also read persuasive essay examples on other topics to master your persuasive techniques!

Tips to Write a Persuasive Essay About Covid-19

Writing a persuasive essay about COVID-19 requires a thoughtful approach to present your arguments effectively.

Here are some tips to help you craft a compelling persuasive essay on this topic:

Choose a Specific Angle

Start by narrowing down your focus. COVID-19 is a broad topic, so selecting a specific aspect or issue related to it will make your essay more persuasive and manageable. For example, you could focus on vaccination, public health measures, the economic impact, or misinformation.

Provide Credible Sources

Support your arguments with credible sources such as scientific studies, government reports, and reputable news outlets. Reliable sources enhance the credibility of your essay.

Use Persuasive Language

Employ persuasive techniques, such as ethos (establishing credibility), pathos (appealing to emotions), and logos (using logic and evidence). Use vivid examples and anecdotes to make your points relatable.

Organize Your Essay

Structure your essay involves creating a persuasive essay outline and establishing a logical flow from one point to the next. Each paragraph should focus on a single point, and transitions between paragraphs should be smooth and logical.

Emphasize Benefits

Highlight the benefits of your proposed actions or viewpoints. Explain how your suggestions can improve public health, safety, or well-being. Make it clear why your audience should support your position.

Use Visuals -H3

Incorporate graphs, charts, and statistics when applicable. Visual aids can reinforce your arguments and make complex data more accessible to your readers.

Call to Action

End your essay with a strong call to action. Encourage your readers to take a specific step or consider your viewpoint. Make it clear what you want them to do or think after reading your essay.

Revise and Edit

Proofread your essay for grammar, spelling, and clarity. Make sure your arguments are well-structured and that your writing flows smoothly.

Seek Feedback

Have someone else read your essay to get feedback. They may offer valuable insights and help you identify areas where your persuasive techniques can be improved.

Tough Essay Due? Hire Tough Writers!

Common Topics for a Persuasive Essay on COVID-19

Here are some persuasive essay topics on COVID-19:

The Importance of Vaccination Mandates for COVID-19 Control
Balancing Public Health and Personal Freedom During a Pandemic
The Economic Impact of Lockdowns vs. Public Health Benefits
The Role of Misinformation in Fueling Vaccine Hesitancy
Remote Learning vs. In-Person Education: What's Best for Students?
The Ethics of Vaccine Distribution: Prioritizing Vulnerable Populations
The Mental Health Crisis Amidst the COVID-19 Pandemic
The Long-Term Effects of COVID-19 on Healthcare Systems
Global Cooperation vs. Vaccine Nationalism in Fighting the Pandemic
The Future of Telemedicine: Expanding Healthcare Access Post-COVID-19

In search of more inspiring topics for your next persuasive essay? Our persuasive essay topics blog has plenty of ideas!

To sum it up,

You have read good sample essays and got some helpful tips. You now have the tools you needed to write a persuasive essay about Covid-19. So don't let the doubts stop you, start writing!

If you need professional writing help, don't worry! We've got that for you as well.

MyPerfectWords.com is a professional persuasive essay writing service that can help you craft an excellent persuasive essay on Covid-19. Our experienced essay writer will create a well-structured, insightful paper in no time!

So don't hesitate and place your ' write my essay online ' request today!

Frequently Asked Questions

Are there any ethical considerations when writing a persuasive essay about covid-19.

Yes, there are ethical considerations when writing a persuasive essay about COVID-19. It's essential to ensure the information is accurate, not contribute to misinformation, and be sensitive to the pandemic's impact on individuals and communities. Additionally, respecting diverse viewpoints and emphasizing public health benefits can promote ethical communication.

What impact does COVID-19 have on society?

The impact of COVID-19 on society is far-reaching. It has led to job and economic losses, an increase in stress and mental health disorders, and changes in education systems. It has also had a negative effect on social interactions, as people have been asked to limit their contact with others.

Write Essay Within 60 Seconds!

Caleb S. has been providing writing services for over five years and has a Masters degree from Oxford University. He is an expert in his craft and takes great pride in helping students achieve their academic goals. Caleb is a dedicated professional who always puts his clients first.

Paper Due? Why Suffer? That’s our Job!

Keep reading

High contrast
Press Centre

Search UNICEF

What you need to know about covid-19 vaccines, answers to the most common questions about coronavirus vaccines..

Available in:

Vaccines save millions of lives each year. The development of safe and effective COVID-19 vaccines are a crucial step in helping us get back to doing more of the things we enjoy with the people we love.

We’ve gathered the latest expert information to answer some of the most common questions about COVID-19 vaccines. Keep checking back as we will update this article as more information becomes available.

What are the benefits of getting vaccinated?

Vaccines save millions of lives each year and a COVID-19 vaccine could save yours. The COVID-19 vaccines are safe and effective, providing strong protection against serious illness and death. WHO reports that unvaccinated people have at least 10 times higher risk of death from COVID-19 than someone who has been vaccinated.

It is important to be vaccinated as soon as it’s your turn, even if you already had COVID-19. Getting vaccinated is a safer way for you to develop immunity from COVID-19 than getting infected.

The COVID-19 vaccines are highly effective, but no vaccine provides 100 per cent protection. Some people will still get ill from COVID-19 after vaccination or pass the virus onto someone else.

Therefore, it is important to continue practicing safety precautions to protect yourself and others, including avoiding crowded spaces, physical distancing, hand washing and wearing a mask.

Who should be vaccinated first?

Each country must identify priority populations, which WHO recommends are frontline health workers (to protect health systems) and those at highest risk of death due to COVID-19, such as older adults and people with certain medical conditions. Other essential workers, such as teachers and social workers, should then be prioritized, followed by additional groups as more vaccine doses become available.

The risk of severe illness from COVID-19 is very low amongst healthy children and adolescents, so unless they are part of a group at higher risk of severe COVID-19, it is less urgent to vaccinate them than these priority groups.

Children and adolescents who are at higher risk of developing severe illness from COVID-19, such as those with underlying illnesses, should be prioritized for COVID-19 vaccines.

When shouldn’t you be vaccinated against COVID-19?

If you have any questions about whether you should receive a COVID-19 vaccine, speak to your healthcare provider. At present, people with the following health conditions should not receive a COVID-19 vaccine to avoid any possible adverse effects:

If you have a history of severe allergic reactions to any ingredients of a COVID-19 vaccine.
If you are currently sick or experiencing symptoms of COVID-19 (although you can get vaccinated once you have recovered and your doctor has approved).

Should I get vaccinated if I already had COVID-19?

Yes, you should get vaccinated even if you’ve previously had COVID-19. While people who recover from COVID-19 may develop natural immunity to the virus, it is still not certain how long that immunity lasts or how well it protects you against COVID-19 reinfection. Vaccines offer more reliable protection, especially against severe illness and death. Vaccination policies after COVID-19 infection vary by country. Check with your health care provider on the recommendation where you live.

Which COVID-19 vaccine is best for me?

All WHO-approved vaccines have been shown to be highly effective at protecting you against severe illness and death from COVID-19. The best vaccine to get is the one most readily available to you.

You can find a list of those approved vaccines on WHO’s site . 

Remember, if your vaccination involves two doses, it’s important to receive both to have the maximum protection.

How do COVID-19 vaccines work?

Vaccines work by mimicking an infectious agent – viruses, bacteria or other microorganisms that can cause a disease. This ‘teaches’ our immune system to rapidly and effectively respond against it.

Traditionally, vaccines have done this by introducing a weakened form of an infectious agent that allows our immune system to build a memory of it. This way, our immune system can quickly recognize and fight it before it makes us ill. That’s how some of the COVID-19 vaccines have been designed.

Other COVID-19 vaccines have been developed using new approaches, which are called messenger RNA, or mRNA, vaccines. Instead of introducing antigens (a substance that causes your immune system to produce antibodies), mRNA vaccines give our body the genetic code it needs to allow our immune system to produce the antigen itself. mRNA vaccine technology has been studied for several decades. They contain no live virus and do not interfere with human DNA.

For more information on how vaccines work, please visit WHO .

Are COVID-19 vaccines safe?

Yes, COVID-19 vaccines have been safely used to vaccinate billions of people. The COVID-19 vaccines were developed as rapidly as possible, but they had to go through rigorous testing in clinical trials to prove that they meet internationally agreed benchmarks for safety and effectiveness. Only if they meet these standards can a vaccine receive validation from WHO and national regulatory agencies.

UNICEF only procures and supplies COVID-19 vaccines that meet WHO’s established safety and efficacy criteria and that have received the required regulatory approval.

How were COVID-19 vaccines developed so quickly?

Scientists were able to develop safe effective vaccines in a relatively short amount of time due to a combination of factors that allowed them to scale up research and production without compromising safety:

Because of the global pandemic, there was a larger sample size to study and tens of thousands of volunteers stepped forward
Advancements in technology (like mRNA vaccines) that were years in the making
Governments and other bodies came together to remove the obstacle of funding research and development
Manufacturing of the vaccines occurred in parallel to the clinical trials to speed up production

Though they were developed quickly, all COVID-19 vaccines approved for use by the WHO are safe and effective.

What are the side effects of COVID-19 vaccines?

Vaccines are designed to give you immunity without the dangers of getting the disease. Not everyone does, but it’s common to experience some mild-to-moderate side effects that go away within a few days on their own.

Some of the mild-to-moderate side effects you may experience after vaccination include:

Arm soreness at the injection site
Muscle or joint aches

You can manage any side effects with rest, staying hydrated and taking medication to manage pain and fever, if needed.

If any symptoms continue for more than a few days then contact your healthcare provider for advice. More serious side effects are extremely rare, but if you experience a more severe reaction, then contact your healthcare provider immediately.

>> Read: What you need to know before, during and after receiving a COVID-19 vaccine

How do I find out more about a particular COVID-19 vaccine?

You can find out more about COVID-19 vaccines on WHO’s website .

Can I stop taking precautions after being vaccinated?

Keep taking precautions to protect yourself, family and friends if there is still COVID-19 in your area, even after getting vaccinated. The COVID-19 vaccines are highly effective against serious illness and death, but no vaccine is 100% effective.  

The vaccines offer less protection against infection from the Omicron variant, which is now the dominant variant globally, but remain highly effective in preventing hospitalization, severe disease, and death. In addition to vaccination, it remains important to continue practicing safety precautions to protect yourself and others. These precautions include avoiding crowded spaces, physical distancing, hand washing, and wearing a mask (as per local policies). 

Can I still get COVID-19 after I have been vaccinated? What are ‘breakthrough cases’?

A number of vaccinated people may get infected with COVID-19, which is called a breakthrough infection. In such cases, people are much more likely to only have milder symptoms. Vaccine protection against serious illness and death remains strong.

With more infectious virus variants such as Omicron, there have been more breakthrough infections. That’s why it's recommended to continue taking precautions such as avoiding crowded spaces, wearing a mask and washing your hands regularly, even if you are vaccinated.

And remember, it’s important to receive all of the recommended doses of vaccines to have the maximum protection.

How long does protection from COVID-19 vaccines last?

According to WHO, the effectiveness of COVID-19 vaccines wanes around 4-6 months after the primary series of vaccination has been completed. Taking a booster to strengthen your protection against serious disease is recommended if it is available to you.

Do the COVID-19 vaccines protect against variants?

The WHO-approved COVID-19 vaccines continue to be highly effective at preventing severe illness and death.

However, the vaccines offer less protection against infection from Omicron, which is the dominant variant globally. That's why it's important to get vaccinated and continue measures to reduce the spread of the virus – which helps to reduce the chances for the virus to mutate – including physical distancing, mask wearing, good ventilation, regular handwashing and seeking care early if you have symptoms.

Do I need to get a booster shot?  

Booster doses play an important role in protecting against severe disease, hospitalization and death.

WHO recommends that you take all COVID-19 vaccine doses recommended to you by your health authority as soon as it is your turn, including a booster dose if recommended.

Booster shots should be given first to high priority groups. Data shows that a booster shot plays a significant role in boosting waning immunity and protecting against severe disease from highly transmissible variants like Omicron.

If available, an additional second booster shot is also recommended for some groups of people, 4-6 months after the first booster. That includes older people, those who have weakened immune systems, pregnant women and healthcare workers.

Check with your local health authorities for guidance and the availability of booster shots where you live. 

What do we know about the bivalent COVID-19 booster doses that have been developed to target Omicron?

Bivalent COVID-19 booster shots have now been developed with both the original strain of the coronavirus and a strain of Omicron. These have been designed to better match the Omicron subvariants that have proven to be particularly transmissible. Lab studies have shown that these doses help you to mount a higher antibody response against Omicron. Both Moderna and Pfizer have developed these bivalent vaccines, and some countries have now approved their use.

Check with your local health authorities for information about the availability of these doses and who can get them where you live. And it’s important to note that the original COVID-19 vaccines continue to work very well and provide strong protection against severe illness from Omicron.

Can I receive different types of COVID-19 vaccines?  

Yes, however, policies on mixing vaccines vary by country. Some countries have used different vaccines for the primary vaccine series and the booster. Check with your local health authorities for guidance where you live and speak with your healthcare provider if you have any questions on what is best for you.

I’m pregnant. Can I get vaccinated against COVID-19?

Yes, you can get vaccinated if you are pregnant. COVID-19 during pregnancy puts you at higher risk of becoming severely ill and of giving birth prematurely.

Many people around the world have been vaccinated against COVID-19 while pregnant or breastfeeding. No safety concerns have been identified for them or their babies. Getting vaccinated while pregnant helps to protect your baby. For more information about receiving a COVID-19 vaccination while pregnant, speak to your healthcare provider.

>> Read: Navigating pregnancy during the COVID-19 pandemic

I’m breastfeeding. Should I get vaccinated against COVID-19?

Yes, if you are breastfeeding you should take the vaccine as soon as it is available to you. It is very safe and there is no risk to the mother or baby. None of the current COVID-19 vaccines have live virus in them, so there is no risk of you transmitting COVID-19 to your baby through your breastmilk from the vaccine. In fact, the antibodies that you have after vaccination may go through the breast milk and help protect your baby. >> Read: Breastfeeding safely during the COVID-19 pandemic

Can COVID-19 vaccines affect fertility?

No, you may have seen false claims on social media, but there is no evidence that any vaccine, including COVID-19 vaccines, can affect fertility in women or men. You should get vaccinated if you are currently trying to become pregnant.

Could a COVID-19 vaccine disrupt my menstrual cycle?

Some people have reported experiencing a disruption to their menstrual cycle after getting vaccinated against COVID-19. Although data is still limited, research is ongoing into the impact of vaccines on menstrual cycles.

Speak to your healthcare provider if you have concerns or questions about your periods.

Should my child or teen get a COVID-19 vaccine?

An increasing number of vaccines have been approved for use in children. They’ve been made available after examining the data on the safety and efficacy of these vaccines, and millions of children have been safely vaccinated around the world. Some COVID-19 vaccines have been approved for children from the age of 6 months old. Check with your local health authorities on what vaccines are authorized and available for children and adolescents where you live.

Children and adolescents tend to have milder disease compared to adults, so unless they are part of a group at higher risk of severe COVID-19, it is less urgent to vaccinate them than older people, those with chronic health conditions and health workers.

Remind your children of the importance of us all taking precautions to protect each other, such as avoiding crowded spaces, physical distancing, hand washing and wearing a mask.

It is critical that children continue to receive the recommended childhood vaccines.

How do I talk to my kids about COVID-19 vaccines?

News about COVID-19 vaccines is flooding our daily lives and it is only natural that curious young minds will have questions – lots of them. Read our explainer article for help explaining what can be a complicated topic in simple and reassuring terms.

It’s important to note that from the millions of children that have so far been vaccinated against COVID-19 globally, we know that side effects are very rare. Just like adults, children and adolescents might experience mild symptoms after receiving a dose, such as a slight fever and body aches. But these symptoms typically last for just a day or two. The authorized vaccines for adolescents and children are very safe.

My friend or family member is against COVID-19 vaccines. How do I talk to them?

The development of safe and effective COVID-19 vaccines is a huge step forward in our global effort to end the pandemic. This is exciting news, but there are still some people who are skeptical or hesitant about COVID-19 vaccines. Chances are you know a person who falls into this category.

We spoke to Dr. Saad Omer, Director at the Yale Institute for Global Health, to get his tips on how to navigate these challenging conversations. >> Read the interview

How can I protect my family until we are all vaccinated?

Safe and effective vaccines are a game changer, but even once vaccinated we need to continue taking precautions for the time being to protect ourselves and others. Variants like Omicron have proven that although COVID-19 vaccines are very effective at preventing severe disease, they’re not enough to stop the spread of the virus alone. The most important thing you can do is reduce your risk of exposure to the virus. To protect yourself and your loved ones, make sure to:

Wear a mask where physical distancing from others is not possible.
Keep a physical distance from others in public places.
Avoid poorly ventilated or crowded spaces.
Open windows to improve ventilation indoors.
Try and focus on outdoor activities if possible.
Wash your hands regularly with soap and water or an alcohol-based hand rub.

If you or a family member has a fever, cough or difficulty breathing, seek medical care early and avoid mixing with other children and adults.

Can COVID-19 vaccines affect your DNA?

No, none of the COVID-19 vaccines affect or interact with your DNA in any way. Messenger RNA, or mRNA, vaccines teach the cells how to make a protein that triggers an immune response inside the body. This response produces antibodies which keep you protected against the virus. mRNA is different from DNA and only stays inside the cell for about 72 hours before degrading. However, it never enters the nucleus of the cell, where DNA is kept.

Do the COVID-19 vaccines contain any animal products in them?

No, none of the WHO-approved COVID-19 vaccines contain animal products.

I’ve seen inaccurate information online about COVID-19 vaccines. What should I do?

Sadly, there is a lot of inaccurate information online about the COVID-19 virus and vaccines. A lot of what we’re experiencing is new to all of us, so there may be some occasions where information is shared, in a non-malicious way, that turns out to be inaccurate.

Misinformation in a health crisis can spread paranoia, fear and stigmatization. It can also result in people being left unprotected or more vulnerable to the virus. Get verified facts and advice from trusted sources like your local health authority, the UN, UNICEF, WHO.

If you see content online that you believe to be false or misleading, you can help stop it spreading by reporting it to the social media platform.

What is COVAX?

COVAX is a global effort committed to the development, production and equitable distribution of vaccines around the world. No country will be safe from COVID-19 until all countries are protected.

There are 190 countries and territories engaged in the COVAX Facility, which account for over 90 per cent of the world’s population. Working with CEPI, GAVI, WHO and other partners, UNICEF is leading efforts to procure and supply COVID-19 vaccines on behalf of COVAX.

Learn more about COVAX .

This article was last updated on 25 October 2022. It will continue to be updated to reflect the latest information.

How to talk to your children about COVID-19 vaccines

Tips for navigating the conversation

How to talk to friends and family about vaccines

Tips for handling tough conversations with your loved ones

COVAX information centre

UNICEF and partners led the largest vaccine procurement and supply operation in history

Skip to main content
Skip to FDA Search
Skip to in this section menu
Skip to footer links

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

U.S. Food and Drug Administration

Search
Menu
News & Events
Speeches by FDA Officials
The Critical Role of Health Care Professionals During the COVID-19 Pandemic - 08/10/2020

Speech | Virtual

Event Title The Critical Role of Health Care Professionals During the COVID-19 Pandemic August 10, 2020

(Remarks as prepared for delivery)

I’m pleased to have the opportunity today to speak with you about COVID-19, the FDA’s role in responding to this public health emergency, and the continuing challenges the agency and the medical profession face as it continues to evolve.

I’d like to begin by thanking Dr. Susan Bailey and the American Medical Association for hosting and moderating this event today, as well as the Reagan Udall Foundation for their continuing support of the FDA.

And I’d like to thank all of the physicians and health care professionals on this call today for your hard work, thoughtfulness, and commitment during this challenging time. Among the heroes who have emerged from this crisis are the health care professionals who have risked their own health to serve their patients. The nation is indebted to you.

As we move forward, we know that the pandemic continues to evolve and the health care community must continue to deliver high-quality care to all patients.

Fortunately, we’ve made significant progress in our understanding of this disease, our ability to combat it, and our efforts to help patients suffering with it.

As health care professionals and scientists, we understand there are no easy answers. We still have much more to learn about this disease, with many unanswered questions. And we need to not only treat patients with the disease, but also to prevent the spread of the disease as we seek effective therapeutics and safe and effective vaccines.

Today, I want to talk to you about some of these challenges and about the nature and importance of science and data as we search for answers.

I also want to speak with you in your role as doctors and other health professionals, who are dealing with very practical questions involving patients – an experience I understand and empathize with from my own practice as an oncologist.

Most importantly, I want to reassure you that the decisions that FDA will have to make in the coming months, with regard to new tests for COVID-19, new therapeutics, and new vaccines, will be based on good science and sound data.

Because of the speed with which we need to make decisions, there has been discussion about whether FDA will compromise any of our scientific principles in reviewing data and making decisions about new products. Let me assure you that we will not cut corners.

All of our decisions will continue to be based on good science and the same careful, deliberative processes which we have always used when reviewing medical products.

It is important that you as medical practitioners not only understand this commitment, but also that you reassure your patients.

We have seen surveys reporting that significant percentages of the public would be reluctant to take a vaccine once available. We hope that you will urge your patients to take an approved vaccine so that we can seek to establish widespread immunity.

We can emerge from this emergency only by working together.

We know that the overwhelming quantities of COVID-19 information and data that seem continually to be expanding can place a significant burden on you as clinicians seeking to respond to patient questions and, when appropriate, modify treatment recommendations.

Indeed, COVID-19 is affecting the practice of medicine in many ways, and the FDA has an important role to play in supporting providers and patients through this evolution. Although it seems as if we’ve been engaged in the battle against COVID-19 for a very long time, in the broader context of disease and science, it’s actually been a relatively short period.

Consider that as recently as this January – just eight months ago – few people, other than a limited group of health care professionals and infectious disease experts, had even heard of the novel coronavirus.

It’s easy for me to recall just how recently SARS-CoV-2 appeared on our national radar. That’s because the first reports of the outbreak began just a few weeks after I was sworn in as FDA commissioner. I’d like to share with you my own experiences and what I have learned in the past six months.

From the very beginning, this has been a perplexing and challenging medical mystery, presenting far more questions than answers. Even for those who have followed this public health crisis from its earliest days, little information or understanding of the disease was available.

We didn’t know, for instance, basic things, such as how aggressive, virulent, or contagious the virus was.

That’s not a comfortable position for health professionals who like to be well informed, particularly when we work at agencies charged with protecting the American public.

I learned quickly that despite the relative lack of knowledge, we at the FDA had to make decisions about relative benefits and risks with the data we had.

The FDA regulates the safety, effectiveness and quality of all medical products – drugs, vaccines, and medical devices. We also regulate food safety, which of course also is critical during a crisis like this.

There is always a steep learning curve in the response to a public health emergency, particularly when it involves a new disease. But this learning curve has been especially steep for all of us.

I am trained, as many of you are, as a scientist. And when this pandemic emerged, I conveyed to the leadership and staff at the FDA that even in the face of the public response to this emergency, we at the FDA needed to apply scientific rigor to any decisions being made, no matter how quickly they needed to be made,

It was reassuring to me that the FDA leadership and staff agreed whole-heartedly with this approach. This is how the FDA has always functioned in its role as a federal agency that makes regulatory decisions based on scientific rigor.

We at the FDA, and you as health care professionals have had to respond to challenges like these in real time.

For this pandemic, in particular, for the FDA this has meant supporting the development of safe and effective medical countermeasures.

These actions also included ensuring that our front-line health care workers had and will continue to have the necessary protective equipment.

Since the beginning of this pandemic, FDA scientists have been immersed in providing essential regulatory advice, guidance, and technical assistance needed to advance the development of tests, therapies, and vaccines.

And it’s meant that we have been vigilant in seeking to prevent the sale of fraudulent products that could harm the public.

To be successful in each of these efforts, we’ve been working hard to strengthen the scientific response. We’ve done this by supporting collaborative efforts, creating open communication channels, and building public-private partnerships.

For example, the FDA has created resources like reference-grade sequence data for SARS-CoV-2 to support research and reference panels for COVID-19 diagnostic tests to support continued developments in testing.

The agency has supported the National Institutes of Health’s public-private partnership for therapeutic and vaccine development.

The FDA has also partnered with a number of external partners to gather real world evidence to help inform our understanding of the natural history of COVID-19, drug utilization and performance of COVID-19 diagnostics and therapeutics.

I’m pleased that so many of you -- and the professional organizations you are part of -- have been involved in some of these collaborative efforts.

It’s essential that we bring forward the best ideas and innovations to support the development of new and effective treatments. Working together has been an instrumental part in our ability to come so far, so fast.

Our approach is consistent with and, indeed, goes to the core of the FDA’s mission; we constantly gather new information and evidence about the disease to inform our actions.

As we learn, we discover more answers. But that, in and of itself, is not enough. We must continue to be vigilant and aggressive, constantly reviewing and evaluating the data as they emerge.

The principle underlying this -- that our decisions must not only be informed by the most rigorous data and best science, but also that the evidence on which we base our continuing review is regularly refreshed and expanded through new experiences and opportunities -- is a basic approach of science.

It’s certainly a personal principle that has been a priority for me throughout my career as a physician and researcher.

We are learning more every day. For example, as doctors have treated more cases of COVID, it has become clear that it is not just a respiratory ailment but can affect many organ systems, including the kidneys and heart, and can also cause vascular complications.

And although initially, many of us believed children were not significantly affected by the COVID-19 virus, subsequent reports from across the United States and Europe showed that some young COVID patients were found to have Pediatric Multisystem Inflammatory Syndrome or PMIS.

These cases exhibited clinical features similar to Kawasaki Disease, a rare inflammatory disease primarily affecting young children, which causes blood vessels to become inflamed or swollen throughout the body.

Similarly, some dermatologists revealed that some of their patients who were later diagnosed with COVID-19 had symptoms that could be due to vasculitis, including frostbite like pain, small itchy eczema-like lesions on their extremities. and reddened patches of skin.

We are all concerned about the reports of rising case counts in different locations across the U.S., particularly in the Sunbelt states.

We have also learned that common sense public health measures such as the wearing of masks, social distancing, hand-washing, protection of the vulnerable, and avoidance of large indoor gatherings particularly in bars, do help stop the spread and mitigate community outbreaks. This is our country’s path forward.

The emerging data also continue to confirm the disproportionate impact of the disease on different communities, based on age, ethnicity, and race.

The Coronavirus Task Force, of which I am a member, continues to carefully analyze and monitor the prevalence of the virus throughout the U.S., using the best available science to track, predict and mitigate the curve of the outbreak. We are closely watching the entire country and working to determine the reason behind any new outbreaks or the spread of the disease.

At the FDA, our work goes beyond analyzing the numbers. Our responsibilities involve a range of efforts relating to the diagnosis, response, and treatment of COVID-19 and supporting solutions to bring an end to this crisis.

This includes facilitating the development of tests, both diagnostic and serologic, supporting the advance of treatments and vaccines for the disease, and working to ensure that health care workers and others have the personal protective equipment and other necessary medical products needed to combat it.

Since day one of this emergency, our focus in addressing these challenges has been to meet the need for speed.

To facilitate the development of new treatments and effective tests, and to make sure we have adequate supplies of essential medical equipment such as ventilators, we’ve redoubled our efforts to employ regulatory flexibility and streamlined processes where needed and appropriate, without compromising science.

The goal has been to use every available tool in our arsenal to move new treatments to patients as quickly as possible while helping ensure safety and efficacy.

We’re moving equally fast in our efforts to help support the development of COVID-19 vaccines.

As this audience is well aware, preventive vaccines for infectious disease are foundational to modern public health.

The FDA is committed to ensuring that potential vaccines for COVID-19 are safe and effective.

In June, the agency issued a guidance outlining key recommendations for vaccine development.

In particular, the agency emphasized the importance of recruiting diverse populations, especially those patients who have been disproportionately affected by the pandemic.

The FDA also recommended in the guidance that sponsors use an endpoint estimate of at least 50%, which could have an important impact on individual and public health, while vaccines with lower efficacy might not.

Several COVID-19 vaccine candidates have recently initiated large-scale clinical trials. While I cannot predict when the results from these studies will be ready, I can promise that when the data are available, the FDA will review them using its established, rigorous, and deliberative scientific review process.

We all understand that only by engaging in an open review process and relying on good science and sound data can the public have confidence in the integrity of our decisions.

One important tool we have used during public health emergencies to support the scientific investigation, is to employ our authority for Emergency Use Authorization (EUA).

An EUA allows the use of unapproved medical products or unapproved uses of approved medical products to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain criteria are met, including that there are no adequate, approved, and available alternatives.

These EUA decisions have been an important part of FDA’s efforts to shape an effective and timely response.

Though EUA decisions are based on emerging scientific evidence, we are continually evaluating and reevaluating that evidence in order to ensure that the known and potential benefits of products outweigh the known and potential risks.

Since the earliest days of the pandemic, we’ve issued EUAs for tests, ventilators, and drug treatments. The FDA has granted more than 190 EUAs for COVID-19 tests and has reviewed more than 200 clinical trials for potential therapies.

Nevertheless, we understand that the pace of FDA announcements and decisions can cause confusion for the public and providers.

For instance, some of you may be wondering whether an EUA changes the approach being used to develop drugs and vaccines. What should doctors tell their patients about what’s going on? What drugs are under development? Which are the safest or most effective?

This is a good opportunity to reiterate that although EUAs may be made on this emergency basis, they are guided by science and by continuous review of the most recent up-to-date evidence available.

Even after an EUA is issued, we regularly review that decision based on emerging information. We make any necessary changes as appropriate. This dynamic process is continually being informed by new data and evidence, and it always seeks to balance the risks with the benefits of every COVID-19 treatment.

Take testing, for example. Since day one, tests have played a key role in the ability to understand and manage this disease. Good, accurate, and reliable tests can help reveal who has the disease or, by virtue of the antibodies in someone’s system, who has been infected with the virus.

We’ve worked with hundreds of test developers, many of whom have submitted emergency use authorization requests to the FDA for tests that detect the virus or antibodies to it.

In light of the circumstances, FDA’s goal has always been to provide the necessary regulatory flexibility to support developers and to provide what patients and the public need as quickly as possible without compromising safety or scientific review.

Early on in this pandemic, the FDA posted a policy that explained that under certain circumstances, FDA did not intend to object to the use of tests that were developed and validated by laboratories prior to authorization of an EUA request. There was a national demand for such tests and we felt it was an appropriate decision to exercise regulatory flexibility concerning the use of these validated tests.

It was soon evident that some of the self-validated tests were not reliable and FDA moved quickly to update the policy in response to the available information.

Today, we have nearly 200 reliable, authorized tests. And we continue to monitor the performance of these tests and encourage the development of new and better tests that will enable us to understand this disease and help patients and the medical community address the challenges.

As we have done since the beginning of the pandemic, we will continue to balance the pressing need for access to diagnostic and antibody tests with our helping to ensure that available tests are accurate and reliable.

This same approach applies to potential treatments for COVID-19. We work closely with partners throughout the government, academia, and drug and vaccine developers to explore, expedite, and facilitate the development of products, and provide guidance and technical assistance to drug manufacturers to expedite clinical trials.

Our Coronavirus Treatment Acceleration Program, or CTAP, which we launched in March, has helped to focus the scientific and technical expertise of the agency’s staff to review potential products according to their scientific merit.

By providing enhanced regulatory support, the FDA has been able to support the initiation of more than 200 trials for COVID-19 therapies over the past few months.

This work is essential to returning us to some semblance of normalcy. After all, we need treatments and cures.

But there’s a corresponding aspect of the FDA’s work that is also essential.

This role is to support you, as physicians and medical providers to help answer your patients’ questions. Certainly, explaining the process, as complicated as it is, is an important piece of the response.

To understand this, it may be instructive to look at some actions we’ve taken with several drugs, each of which were granted an EUA, and that received significant public attention.

Back in March, the FDA granted an EUA to allow the drugs chloroquine phosphate and hydroxychloroquine sulfate to be used to treat certain hospitalized COVID-19 patients when a clinical trial was unavailable, or when participation in a clinical trial was not feasible. Early but limited research indicated that the drugs, which are approved to treat malaria and have a well-understood safety profile, might be effective in treating COVID.

After the EUA was issued, FDA continued to monitor the emerging clinical evidence on the use of these drugs in COVID-19 patients.

Based on null results from randomized controlled trials and further analysis of clinical pharmacology information, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 in the patient population covered by the EUA and no longer met the legal criteria for emergency use. As a result, we revoked the EUA in June.

Separately, the FDA issued an EUA for the antiviral drug remdesivir in May.

A randomized trial led by the National Institutes of Health found that remdesivir helped to reduce the length of hospitalization for COVID-19 patients. Additional trials have been completed or are planned to help us understand the appropriate role for remdesivir in this COVID crisis.

Because of the nature of the pandemic, there may be confusion or a lack of understanding about the actions we have taken on therapeutics.

We rely on you in the medical community to answer patients’ inevitable questions about treatments and vaccine development. It is our responsibility at the FDA to provide you with the information you need for your patients.

The fundamental message that we need to communicate is that the FDA’s decisions are based on science, that decisions sometimes change based on our careful review of the most recent evidence, and that we are committed to ensuring that the drugs we approve are safe and effective based on reliable data.

Physicians and other health care professionals have other important roles and responsibilities. One they share with the FDA is to help ensure that the public gets the products they are being promised and to be aware of and avoid scams being perpetrated on them.

The FDA regularly warns consumers to be cautious of websites and stores selling products with unproven claims to prevent, treat, diagnose or cure COVID-19 or unauthorized test kits. The FDA has not evaluated these fraudulent products for safety and effectiveness, and these products might actually be dangerous to patients.

To help tackle the issue of health fraud during the pandemic, the FDA launched Operation Quack Hack, which monitors online marketplaces for fraudulent products and identifies misinformation about COVID-19.

The agency has identified more than 700 fraudulent and unproven medical products related to COVID-19 and has collaborated with the Federal Trade Commission to issue warning letters to firms marketing products with misleading claims, and sent more than 150 reports to online marketplaces, and more than 250 abuse complaints to domain registrars to date.

We make most of this information available on our website and encourage doctors to become familiar with this resource and share this information with their patients.

Physicians have an important role in this area because of your ability to identify and track patients who take illegitimate or black-market drugs.

There is currently no cure for the coronavirus, and it is important for doctors to help inform patients about dangerous products and unscrupulous marketers who may be selling products with false or misleading claims.

Eight months into the pandemic, we have made important progress. Yet with cases continuing to rise, it is evident that further action is needed for our country to chart a course for recovery.

The FDA is launching the COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) to help apply best practices and lessons learned from the emergency response to date. Our goal is to make needed adjustments to support the ongoing COVID-19 response, while also strengthening our resilience and improving our capacity to respond to public health emergencies in the future.

As doctors, we ensure that our treatment plans for our patients are adjusted according to the latest evidence.

I believe this same principle applies to the FDA, which as a science-based agency, is committed to continuous improvement by examining the data and modernizing our approaches when needed.

As we identify lessons and make subsequent changes, we are committed to proactively communicating any forthcoming regulatory changes to doctors and other health professionals.

Though we don’t have all the answers, we do know is that the COVID-19 virus will be with us for the foreseeable future. We are still far from understanding every aspect of this disease.

But the FDA will continue to operate with patient safety and scientific integrity as our North Star. It is this approach that continues to guide the development of new technologies and necessary regulations for safeguarding public health for the present and future.

Our goal is to provide you with the information and understanding you need to ensure that patients receive the support, attention and treatment they deserve. We look forward to working with you to achieve that goal.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Publications
Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

Advanced Search
Journal List
Elsevier - PMC COVID-19 Collection

Persuasive messaging to increase COVID-19 vaccine uptake intentions

Erin k. james.

a Yale Institute for Global Health, New Haven, CT, USA

b Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA

Scott E. Bokemper

c Institution for Social and Policy Studies, Yale University, New Haven, CT, USA

d Center for the Study of American Politics, Yale University, New Haven, CT, USA

Alan S. Gerber

e Department of Political Science, Yale University, New Haven, CT, USA

Saad B. Omer

f Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

g Yale School of Nursing, West Haven, CT, USA

Gregory A. Huber

Associated data.

Widespread vaccination remains the best option for controlling the spread of COVID-19 and ending the pandemic. Despite the considerable disruption the virus has caused to people’s lives, many people are still hesitant to receive a vaccine. Without high rates of uptake, however, the pandemic is likely to be prolonged. Here we use two survey experiments to study how persuasive messaging affects COVID-19 vaccine uptake intentions. In the first experiment, we test a large number of treatment messages. One subgroup of messages draws on the idea that mass vaccination is a collective action problem and highlighting the prosocial benefit of vaccination or the reputational costs that one might incur if one chooses not to vaccinate. Another subgroup of messages built on contemporary concerns about the pandemic, like issues of restricting personal freedom or economic security. We find that persuasive messaging that invokes prosocial vaccination and social image concerns is effective at increasing intended uptake and also the willingness to persuade others and judgments of non-vaccinators. We replicate this result on a nationally representative sample of Americans and observe that prosocial messaging is robust across subgroups, including those who are most hesitant about vaccines generally. The experiments demonstrate how persuasive messaging can induce individuals to be more likely to vaccinate and also create spillover effects to persuade others to do so as well.

The first experiment in this study was registered at clinicaltrials.gov and can be found under the ID number {"type":"clinical-trial","attrs":{"text":"NCT04460703","term_id":"NCT04460703"}} NCT04460703 . This study was registered at Open Science Framework (OSF) at: https://osf.io/qu8nb/?view_only=82f06ecad77f4e54b02e8581a65047d7.

1. Introduction

The global spread of COVID-19 created an urgent need for safe and effective vaccines against the disease. However, even though several successful vaccines have become available, vaccine hesitancy in the general population has the potential to limit the efficacy of vaccines as a tool for ending the pandemic. For instance, in the United States, the public’s willingness to receive a vaccine has declined from 72 % saying they would be likely to get a COVID-19 vaccine in May 2020 to 60 % of people reporting that they would receive a vaccine as of November 2020 [ 1 ]. Given the considerable amount of skepticism about the safety and efficacy of a COVID-19 vaccine, it has become increasingly important to understand how public health communication can play a role in increasing COVID-19 vaccine uptake.

Vaccination is both a self-interested and a prosocial action [ [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] ]. By getting vaccinated, people protect themselves from a disease, but they also reduce the chance that they become a vector through which the disease spreads to others. If enough people receive a vaccine, the population gains protection through herd immunity, but this also creates an incentive for an individual to not get vaccinated because they can forgo vaccination and receive protection from others who do vaccinate. Recent research on vaccination in general has demonstrated that people view vaccination as a social contract and are less willing to cooperate with those who choose not to get inoculated [ 10 ]. This work also implies that highlighting the reputational costs of choosing not to vaccinate could be an effective strategy for increasing uptake. Further, appeals to herd immunity and the prosocial aspect of vaccination have been shown to increase uptake intentions [ [11] , [12] , [13] ], but emphasizing the possibility of free riding on other’s immunity reduces the willingness to get vaccinated [ 14 ].

Focusing specifically on vaccination against COVID-19, recent studies have found that messages that explain herd immunity increase willingness to receive a vaccine [ 15 ] and reduces the time that people would wait to get vaccinated when a vaccine becomes available to them [ 16 ]. However, other work has found that prosocial appeals did not increase average COVID-19 vaccination intentions [ 17 ] and the effect of prosocial concerns was present in sparsely populated places, but absent in more densely populated ones [ 18 ]. Given the current state of evidence, it is unclear whether appealing to getting a COVID-19 vaccine as a way to protect others will increase willingness to vaccinate.

Viewing vaccination through the lens of a collective action problem suggests that in addition to increasing individuals’ intentions to receive a vaccine, effective public health messages would also increase people’s willingness to encourage those close to them to vaccinate and to hold negative judgments of those who do not vaccinate. By encouraging those close to them to vaccinate, people are both promoting compliance with social norms and increasing their own level of protection against the disease. Also, by judging those who do not vaccinate more negatively, they apply social pressure to others to promote cooperative behavior. This would be consistent with theories of cooperation, like indirect reciprocity or partner choice, that rely on free riders being punished or ostracized for their past actions to encourage prosocial outcomes [ [19] , [20] , [21] , [22] , [23] ]. Thus, effective messaging could have outsized effects on promoting vaccination if it both causes people to vaccinate themselves and to encourage those around them to do so.

We conducted two pre-registered experiments to study how different persuasive messages affect intentions to receive a COVID-19 vaccine, willingness to persuade friends and relatives to receive one, and negative judgments of people who choose not to vaccinate. In the first experiment, we tested the efficacy of a large number of messages against an untreated control condition (see Table 1 for full text of messages). A subgroup of the messages in Experiment 1 drew on this collective action framework of vaccination and emphasized who benefits from vaccination or how choosing not to vaccinate hurts one’s social image. A second subgroup drew on contemporary arguments about restrictions on liberty and economic activity during the COVID-19 pandemic. In Experiment 2, we retested the most effective messages from Experiment 1 on a nationally representative sample of American adults. By utilizing this test and re-test design, we guard against false positive results that are observed by chance among the large number of messages tested in Experiment 1. In our analysis of both experiments, we examined whether specific messages were more effective among certain subgroups of the population.

Experimental treatment messages for Experiment 1 and Experiment 2. All messages add the prose in the table to the content of the Baseline informational control. All of the messages in the table were tested in Experiment 1. The messages that are bolded were retested in Experiment 2.

Experiment 1 was fielded in early July 2020. Participants were randomly assigned to either a placebo control condition in which they read a story about the effectiveness of bird feeders or one of eleven treatment messages. The first message is a Baseline informational control condition that describes how it is important to receive a vaccine to reduce your risk of contracting COVID-19 or spreading it to others. Informational messages have been shown to be effective at increasing COVID-19 vaccine uptake intentions [ 24 ]. This message also emphasized that vaccines are safe and estimated to save millions of lives per year. The other messages add additional content to this baseline message.

The subgroup of messages that emphasized collective action varied who would benefit from vaccination or what other people might think of someone who chooses to be a free rider by not vaccinating. Focusing on who benefits from vaccination, the second message invoked Self Interest and reinforced the idea that vaccination is a self-protecting action (“Remember, getting vaccinated against COVID-19 is the single best way to protect yourself from getting sick.”). The third message, Community Interest, instead argued that vaccination is a cooperative action to protect other people (“Stopping COVID-19 is important because it reduces the risk that members of your family and community could get sick and die.”). This message also invoked reciprocity by emphasizing the importance of every-one working together to protect others.

The fourth, fifth, and sixth messages added an invocation of an emotion, Guilt, Embarrassment, or Anger, to the Community Interest message. These messages prompted people to think about how they would feel if they chose not to get vaccinated and spread COVID-19 to someone else in the future. Emotions are thought to play a role in cooperation, either by motivating an individual to take an action because of a feeling that they experience or restraining them from taking an action because of the emotional response it would provoke in others [ [25] , [26] , [27] ]. Further, anticipated emotional states have been shown to promote various health behaviors, like vaccination [ [28] , [29] ].

The seventh and eighth messages evoked concerns about one’s reputation and social image, which influences their attractiveness as a cooperative partner to others. The seventh, a Not Bravery message, reframed the idea that being unafraid of the virus is not a brave action, but instead selfish, and that the way to demonstrate bravery is by getting vaccinated because it shows strength and concern for others (“To show strength get the vaccine so you don’t get sick and take resources from other people who need them more”). The eighth message was a Trust in Science message that highlights that scientists believe a vaccine will be an effective way of limiting the spread of COVID-19. This message suggests that those who do not get vaccinated do not understand science and signal this ignorance to others (“Not getting vaccinated will show people that you are probably the sort of person who doesn’t understand how infection spreads and who ignores or are confused about science.”).

The final three messages drew on concerns about restrictions on freedom and economic activity that were widespread during the COVID-19 pandemic. A pair of messages focused on how vaccination would allow for a restoration of Personal Freedom (“Government policies to prevent the spread of COVID-19 limit our freedom of association and movement”) or Economic Freedom (“Government policies to prevent the spread of COVID-19 have stopped businesses from opening up”). These messages take a value that is commonly invoked in individuals’ decision to not vaccinate [ [30] , [31] ] and reframed vaccination as something that would actually restore freedoms that had been taken away. The final message, Community Economic Benefit, argues that a vaccine will help return people’s financial security and strengthen the economy This message is similar to the Community Interest messages that are described above, but instead focuses on cooperating to restore the economy (“We can all end this outbreak and strengthen the national economy by working together and getting vaccinated”).

2.1. Experiment 1 results

Panel A of Fig. 1 plots the effect of each vaccine message relative to the untreated control group on intention to vaccinate. The intention to vaccinate measure was formed by combining responses to a question about the likelihood of getting a COVID-19 vaccine within the first 3 months that one is available with a question about getting a vaccine within the first year that one is available. Specifically, for respondents who did not answer that they were very likely to vaccinate within the first three months that a vaccine is available to them, we asked how likely they would be to vaccinate within a year. This measure coded those who are very likely in the first three months at the highest value on the scale followed by very likely within a year descending down to very unlikely within the first year. Analyzing the vaccination item separately does not substantively change the results. All outcome variables were scored 0 to 1, with higher values indicating greater willingness to endorse the pro-vaccine action or belief (Underlying regressions appear in Table S1 and unless otherwise noted, all analyses were pre-registered).

An external file that holds a picture, illustration, etc.
Object name is gr1_lrg.jpg

Experiment 1. Messages that frame vaccination as a cooperative action to protect others or emphasize how non-vaccination might negatively affect one’s social image increase reported willingness to advise a friend, and judgment of non-vaccinators. Panel A displays treatment effects for the combined measure of intention to vaccinate, Panel B displays the advise a friend outcome, and Panel C displays the judging a non-vaccinator outcome. Treatment effects for both panels were estimated using OLS regression that included covariates. The effects displayed are a comparison against the placebo control baseline and are presented with 95% confidence intervals. The dashed vertical line is the effect of the Baseline informational control for each outcome.

Compared to the untreated control, the Baseline informational message was associated with modest increases in intention to vaccinate by 0.034 units (95 % CI:0.002, 0.065; p < .05). This effect represents an increase of approximately 6 % in the scale score compared to the outcome in the control condition.

By comparison, the Community Interest, Community Interest + Guilt, Embarrassment, or Anger, Not Bravery, Trust in Science and Personal Freedom messages all produce larger effects, at least qualitatively, than the Baseline informational message on the intention to vaccinate outcome. Effects for the Self-Interest, Economic Freedom, and Community Economic benefit messages were not consistently distinguishable from the untreated control group outcomes, and their effects were indistinguishable from the effects of the Baseline informational message.

The most promising messages were the Not Bravery, Community Interest, and Community Interest + Embarrassment messages. These messages were associated with effects that were statistically distinguishable from the untreated control group (Not Bravery: 0.077 units, 95 % CI: 0.035, 0.119; p < .01, Community Interest: 0.090 units, 95 % CI: 0.050, 0.129; p < .01, Community Interest + Embarrassment: 0.094 units, 95 % CI: 0.054, 0.134; p < .01) at p < .01. Moreover, their effects were always more than twice as large as the Baseline informational treatment and these differences were significant at p < .05 (two-tailed tests). The effects of the Trust in Science message and the Personal Freedom message were not statistically significant when compared to the Baseline informational message.

To put the magnitudes of the effects into context, we re-estimated our analysis after dichotomizing the intended vaccine uptake measure such that those who report they were “somewhat” or “very” likely to get the vaccine, either with three months or a year, are coded as 1 and those who do not are coded 0 (this analysis was not pre-registered). This produced a predicted rate of intended vaccination in the control group of 58.2 %. Respondents who read the Baseline informational message were 7.4 percentage points (95 % CI: 2.9 pp, 12.0 pp; p < .01) more likely to receive a vaccine. Among those assigned to the Not Bravery or Community Interest messages it was predicted to increase by 10.4 percentage points and 12.7 percentage points (Not Bravery: 95 % CI: 4.3 pp, 16.4 pp; p < .01, Community Interest: 95 % CI: 6.7 pp, 18.7 pp; p < .01) respectively, while among those assigned to the Community Interest + Embarrassment message it was predicted to increases by 15.9 percentage points (95 % CI: 10.2 pp, 21.6 pp; p < .01). This last difference was substantively large, representing a proportional increase of 27 % (0.159/0.582) compared to the control condition and a 13 % increase compared to the Baseline informational condition (0.159-0.074)/(0.582 + 0.074).

Turning to the other regarding outcomes that focused on spurring action by others, Panel B plots the effects of each vaccine message relative to the untreated control for advising a friend to receive a vaccine and Panel C plots the effects for negatively judging someone who refuses to receive one. Here, the effect of the Baseline informational intervention was modest and statistically insignificant. However, the Not Bravery, Trust in Science, Personal Freedom, Community Interest, Community Interest + Guilt, and Community Interest + Embarrassment messages had larger effects on both outcomes that were statistically distinguishable from the control outcome.

The most promising message was the Community Interest + Embarrassment message for the advise a friend outcome, which was associated with a 0.09 unit increase in the scale outcome (95 % CI: 0.049, 0.132; p < .01 two-tailed test), an effect that represents an increase of 27 % compared to the mean scale score in the control group. The effect was 0.067 units compared to the Baseline informational message (95 % CI: 0.027, 0.105; p = .001, two-tailed test). We conducted a similar exercise to the one describe above to gauge the relative magnitude of these treatment effects. For the Community Interest + Embarrassment message we estimated a 15 percentage point increase (95 % CI: 0.088, 0.209; p < .01, two tailed test,) in a binary intention to advise others to vaccinate outcome, a proportional increase of 27 % compared to the control group baseline of 53 % (0.15/0.53). This effect was also 6 percentage points larger than the effect of the baseline message (95 % CI: 0.008, 0.121; p = .03, two-tailed test).

The most promising outcome for the negative judgment of non-vaccinators was the Not Bravery message, which had an effect of 0.09 scale points (95 % CI: 0.052, 0.126; p < .01, two-tailed test) compared to the untreated control and 0.072 scale points versus the Baseline information (95 % CI: 0.037, 0.106; p < .01 Baseline message, two-tailed tests). This corresponded to a 21 % increase compared to the scale outcome in the control group (0.09/0.43). These are both substantively and statistically meaningful effects. The Community Interest, Community Interest + Guilt, Community Interest + Embarrassment, Trust in Science, and Personal Freedom messages all produced effects that were statistically distinguishable from the control condition.

We also investigated the robustness of these findings to sample restrictions and whether certain subgroups were more responsive to specific treatment messages (reported in Figures S2-S12 ). Results were generally robust to restricting the sample to those who were over the 10th percentile and under the 90th percentile for completion time. For subgroup analyses, those scoring low in liberty endorsement appeared more responsive to the Baseline treatment and to the Not Bravery message than are those who scored high in liberty endorsement. Those who report being less likely to take risks appeared robustly more responsive to the Not Bravery message than those who were high in risk taking. Those who were high in risk taking appear more responsive to the Personal Freedom message with regard to their own behavioral intentions. Certain groups appeared generically easier to persuade (Democrats rather than Republicans, an important divide that has emerged during the pandemic [ 32 ], and Women rather than Men), but there were no clear differences in which treatments appeared most effective across these groups. We explored the robustness of these subgroup differences in Experiment 2.

Taken together, the most successful messages in Experiment 1 were those that were theoretically motivated by viewing vaccination as a collective action problem. Consistent with previous work that demonstrates that prosocial appeals are effective in promoting vaccination, the Community Interest message and Community Interest + Guilt, Embarrassment, or Anger messages increased COVID-19 vaccine uptake intentions. Moving beyond who benefits from vaccination, the Not Bravery and Trust in Science messages that invoked concerns about one’s social image if they choose not to vaccinate also increased uptake intentions. All of the collective action oriented messages increased intentions to advise a friend to vaccinate and negative judgments of those who do not, potentially creating spillover effects that induce others to vaccinate. In addition to this subgroup of messages, we found that reframing vaccination as a way to restore freedom was also effective, though the other messages motivated by contemporary debates about the pandemic were generally no more effective than the Baseline condition.

2.2. Experiment 2 results

Experiment 2 tested the subset of the best performing messages from Experiment 1 on a nationally representative sample in September 2020. Notably, in the several month period between Experiment 1 and Experiment 2, the public had grown increasingly skeptical of a potential COVID-19 vaccine [ 1 ]. Panel A of Fig. 2 plots the effect of each vaccine message, relative to the untreated control group, on the same measure of intention to vaccinate used in Experiment 1. (The model specifications shown in the figure were from our pre-registered specifications, underlying regression appear in Table S2.). Given that we observed the messages from Experiment 1 were effective at increasing vaccine uptake, we pre-registered directional hypotheses for Experiment 2 that tested whether the effects could be replicated on a nationally representative sample. Accordingly, we report one-tailed hypothesis tests and 90 % confidence intervals in the results presented below. Results largely confirmed the patterns observed in Experiment 1.

An external file that holds a picture, illustration, etc.
Object name is gr2_lrg.jpg

Experiment 2. The Not Bravery, Community Interest, and Community Interest + Embarrassment messages increase both intentions to vaccinate and other-regarding outcomes. Panel A displays treatment effects for intentions to vaccinate, Panel B displays the advise a friend, and Panel C displays the judging a non-vaccinator outcomes. Treatment effects for both panels were estimated using OLS regression that included covariates. The effects displayed are a comparison against the placebo control baseline and are presented with 90 % confidence intervals. The dashed vertical line is the effect of the Baseline informational control for each outcome.

The Baseline informational treatment was associated with a modest increase, 0.029 units, in intention to vaccinate (90 % CI: 0.011, 0.046; p < .01, one-tailed test). This effect was a 6 % increase of the observed scale outcome in the untreated control group.

The Community Interest and Community Interest + Embarrassment messages were associated with qualitatively larger effects on intended vaccine uptake. These messages were associated with increases of 0.045 units (90 % CI: 0.021, 0.070; p < .01, one-tailed test) and 0.043 units (90 % CI: 0.019, 0.067; p < .01, one-tailed test), respectively. As with Experiment 1, we recoded those who stated they were “somewhat” or “very” likely to receive the vaccine as 1 and those who did not report that they were likely to receive it as 0 (this analysis was not pre-registered: for consistency we report 90 % confidence intervals). This binary measure produced a predicted rate of intended vaccination in the control group of 51.4 %. Intended uptake was 3.3 percentage points higher in the Baseline information condition (90 % CI: 0.5 pp, 6.0 pp; p < .05, one-tailed test), 3.5 percentage points higher in the Community Interest + Embarrassment condition (90 % CI: −0.1 pp, 7.0 pp; p = .06, one-tailed test), and 5 percentage points higher in the Community Interest condition (90 % CI: 1.3 pp, 0.8.7 pp; p < .05, one-tailed test). The latter effect was proportionally large—10 % compared to the baseline predict rate in the control group (0.050/0.514).

On average, the Not Bravery, Trust in Science, and Personal Freedom messages were approximately as effective as the informational content to which they were added in increasing intention to vaccinate, which differs from Experiment 1 where they modestly outperformed the Baseline informational condition.

Turning to other regarding outcomes, Panel B of Fig. 2 plots effects for advice given to others and Panel C does so for negative judgments of non-vaccinators. The Baseline informational treatment was again associated with statistically significant increases in each outcome. For these outcomes, the Not Bravery, Trust in Science, and both Community Interest messages produced effects that were at least descriptively larger than the Baseline treatment. The effects for the Personal Freedom message were smaller than the Baseline informational treatment, a result that again diverged from Experiment 1.

In terms of advising others to vaccinate, the most effective message was the Community Interest + Embarrassment message, which was also the most effective message in Experiment 1. This effect was 0.07 scale points (90 % CI: 0.043, 0.095; p < .01, one-tailed test), an increase of 14 % compared to the control group average scale score of 0.51 (0.07/0.51). This effect was also statistically distinguishable from the effect of the Baseline informational treatment (difference = 0.045; 90 % CI: 0.020, 0.069; p < .01, one-tailed test). When dichotomizing the advise a friend outcome to better describe the magnitude of the effect, we estimated that the Community interest + Embarrassment message was associated with a 10 percentage point increase (90 % CI: 0.064, 0.140; p < .01, one-tailed test) in intention to advise others to vaccinate compared to the control group, a proportional increase of 27 % compared to the control group baseline of 38 % (0.10/0.38). This effect was approximately 6 points larger than the effect of the Baseline message (90 % CI: 0.026, 0.099; p < .01, one-tailed test).

In terms of judging non-vaccinators, the largest effects were for the Not Bravery and Trust in Science messages, with each effect also statistically distinguishable from the Baseline message. Notably, in this sample the Trust in Science message had large effects on beliefs and actions toward others but appeared ineffective in changing an individual’s own intended vaccination behavior. The Not Bravery message was also the most effective message in this regard in Experiment 1.

We examined three pre-registered differences in subgroup treatment effects to test the patterns observed in Experiment 1. First, confirming Experiment 1 we found that those who did not endorse liberty values were more responsive to the Not Bravery message (compared to the baseline message) than those who endorsed liberty values for the three outcome measures. Second, we did not confirm either preregistered prediction with regard to differences in treatment effects by risk taking that were observed in Experiment 1.

The remaining subgroup comparisons were not pre-registered. Beginning with gender, in comparison to the untreated control, women responded more to the Trust in Science and Community Interest + Embarrassment message than did men (all five outcomes), while men responded more to the Not Bravery and Community Interest (without embarrassment) messages. Democrats were more responsive than Republicans across the board to the different treatment messages, while Republicans appeared to react only to the Community Interest and Community Interest + Embarrassment messages (magnitudes similar to those of Democrats). We observed a similar pattern for differences by baseline vaccine confidence, measured pre-treatment with a multi-item battery of questions [ 33 ]. Those high in vaccine confidence responded to all messages, while those low in confidence responded reliably only to the Community Interest messages.

3. Discussion

Overall, the results point both to a set of effective messages and the potential efficacy of specific messages for some particular subgroups. On average, a simple informational intervention is effective, but it is even more effective to add language framing vaccine uptake as protecting others and as a cooperative action. Not only does emphasizing that vaccination is a prosocial action increase uptake, but it also increases people’s willingness to pressure others to do so, both by direct persuasion and negative judgment of non-vaccinators. The latter social pressure effects may be enhanced by highlighting how embarrassing it would be to infect someone else after failing to vaccinate. The Not Bravery and Trust in Science messages had substantial effects on other regarding outcomes and for some subgroups, but do not appear to be as effective as the Community Interest messages in promoting own vaccination behavior. Importantly, in distinct samples fielded several months apart, the Community Interest, Community Interest + Embarrassment, and the Not Bravery messages produced substantively meaningful increases for all outcomes measures relative to the untreated control, and in some instances did so in comparison to the Baseline information condition.

Our findings are consistent with the idea that vaccination is often treated as a social contract in which people are expected to vaccinate and those who do not are sanctioned [ 10 ]. In addition to messages emphasizing the prosocial element of vaccination, we observed that messages that invoked reputational concerns were successful at altering judgment of those who would free ride on the contributions of others. This work could also help explain why social norm effects appear to overwhelm the incentive to free ride when vaccination rates are higher [ [34] , [35] ]. That is, messages that increased intentions to vaccinate also increased the moralization of non-vaccinators suggesting that they are fundamentally linked to one another. These messages will need to be adapted in specific cultural contexts with relevant partners, such as community leaders.

The robust effect of the Community Interest message advances our current understanding of whether public health messaging that deploys prosocial concerns could be effective at increasing COVID-19 vaccine uptake. The results of both experiments presented here support prior work that demonstrated the effectiveness of communication that explains herd immunity on promoting vaccination [ [15] , [16] ]. It also suggests that a detailed explanation of herd immunity may not be necessary to induce prosocial behavior.

Beyond the theoretical contribution, the results have practical implications for vaccine communication strategies for increasing COVID-19 vaccine acceptance. We identified multiple effective messages that provide several evidence-based options to immunization programs as they develop their vaccine communication strategies. Importantly, the insights into differential effectiveness of various messages by subgroup (e.g. men vs women) could inform messaging targeted to specific groups. Understanding heterogeneous treatment effects and the mechanisms that cause differential responses to persuasive messaging strategies requires additional testing and theoretical development. We view this as a promising avenue for future work.

The experiments presented here are not without limitations. First, we measured intentions to vaccinate at a time when a vaccine was not currently available and the effectiveness and side effects of potential vaccines were not known. This also meant that we could not observe actual vaccination behavior, which is ultimately the outcome of interest. While intentions predict behavior in many contexts [ [36] , [37] ] including vaccination [ [38] , [39] , [40] ], past research examining the effect of behavioral nudges on COVID-19 vaccine uptake has produced divergent evidence when testing the effect of the same treatments in the field on behavior and in a survey experiment on a behavioral intention [ 41 ]. This observation highlights the need for field testing messages that have shown to be successful on increasing uptake intentions in survey experiments to ascertain whether they also increase vaccine uptake. It may be that field tests reveal certain messages are particularly less effective than in the survey context, or that messages are uniformly less effective. Second, given the rapidly evolving nature of the COVID-19 pandemic, attitudes about vaccines may have changed since the experiments were fielded which could also change the efficacy of the messages that we tested. Third, we cannot be sure whether, or how long, the effects we observe here persist. Finally, we only tested text-based messages, but public health messaging is delivered through many mediums, like public service announcements, videos, and images. Future work can adapt the successful messaging strategies found here and test their efficacy when delivered in alternative formats.

Efforts to vaccinate individuals against COVID-19 are currently underway in the United States and it remains important to convince the mass public of the safety and efficacy of COVID-19 vaccines to ensure that the threshold for herd immunity is reached. Our experiments provide robust evidence that appealing to protecting others has effects on intentions to get vaccinated and to apply social pressure to others to do so as well.

4. Materials and methods

4.1. ethics statement.

The experiments reported here were fielded under an exemption granted by the Yale University IRB. Informed consent was obtained from participants and they were informed that they could stop the study at any time. Data was collected anonymously and contained no personally identifiable information.

4.2. Experiment 1

Participants and Procedure. Participants were recruited by the vendor Luc.id to take a survey. Of those who were recruited, 4,361 participants completed the survey. An examination of attrition during the survey reveals that attrition was balanced across groups which minimizes concerns that the treatment effects estimated in the main manuscript are affected by attrition. The survey was programmed using the survey software Qualtrics. The survey was fielded between July 3, 2020 and July 8, 2020.

Experimental Design. Participants first completed basic demographic and pre-treatment attitudinal questions and were asked about their experience with COVID-19. After this, participants read a treatment message. They were required to spend at least 20 s on the survey page that contained the message to given them an adequate amount of time to read it. We allocated 2/15 of the sample to the untreated control condition and 1/5 of the sample to the Information baseline condition due to the number of comparisons that would utilize these conditions. Each of the remaining conditions received 1/15 of the sample. The design and analysis were pre-registered at ClinicalTrials.gov (protocol ID: 2000027983).

Outcome Measures. For COVID-19 vaccine uptake intentions, participants were asked “How likely are you to get a COVID-19 vaccine within the first 3 months that it is available to you?” and “How likely are you to get a COVID-19 vaccine in the first year that it is available to you?” Respondents answered this question on a five-point scale with end points of “Extremely unlikely” and “Extremely likely.” The main text describes how these items were combined for analysis. Turning to the likelihood of advising someone to vaccinate, respondents were asked “How likely are you to advise a close friend or relative to get vaccinated against COVID-19 once a vaccine becomes available?” Respondents also answered this question on a five-point scale with end points of “Extremely unlikely” and “Extremely likely.” Finally, for judging someone who chooses not to vaccinate, respondents read “we would like you to think about a friend or relative who chose not to receive a COVID-19 vaccine when it is available. What would you think about this person? Are they…”. This prompt was followed by four traits: trustworthy, selfish, likeable, and competent. The response options were “not at all”, “slightly”, “somewhat”, “mostly”, and “very.”

Analysis. We used OLS regression with robust Huber-White standard errors and indicators for assigned treatment to estimate treatment effects. We use robust standard errors to address the heteroscedasticity observed when estimating our primary analysis models without them. We included covariates as described in the Supplementary Materials . Comparisons across treatments are from linear combination of coefficients tests. For the subgroup analyses, we restricted the sample to the stated criteria and estimate the model specified here on the subsample. For liberty endorsement and risk taking, we determined who was high and low by splitting the sample at the mean.

4.3. Experiment 2

Participants and Procedure. Participants ( n = 5,014) were recruited by the vendor YouGov/Polimetrix. YouGov provides subjects using a sampling procedure that is designed to match a number of Census demographics. To determine the sample size, we conducted a power analysis to detect effects that were 80 % as large as those observed in Experiment 1. The experiment was fielded between September 9, 2020 and September 22, 2020.

Experimental Design. Participants first completed basic demographic and pre-treatment attitudinal questions and were asked about their experience with COVID-19. Participants were randomly assigned to one of seven conditions: the untreated control, the Information baseline control, Community Interest, Community Interest + Anticipated Embarrassment, Not Bravery, Trust in Science, or Personal Freedom. As in Experiment 1, more participants were assigned to the untreated control condition and the Baseline information control condition, 1/5 and 3/10 of the sample respectively. The remaining five conditions each received 1/10 of the sample. Participants were required to spend at least 30 s on the survey page that had the treatment message. The design and analysis were pre-registered at Open Science Framework.

Outcome Measures. The outcome measurement was the same as described in Experiment 1 with the exception of intelligent being added to the judgment of a non-vaccinator scale.

Analysis. We used the same modeling approach described above to produce the results displayed in Fig. 2 . We included covariates as described in the Supplementary Materials . For subgroup analyses, we estimated OLS regression models with an indicator variable if a person was a member of a subgroup (e.g. high endorsement of liberty) and zero otherwise.

CRediT authorship contribution statement

Erin K. James: Conceptualization, Writing- original draft, Writing- review and editing. Scott E. Bokemper: Conceptualization, Data curation, Formal analyses. Alan S. Gerber: Conceptualization, Writing- review and editing. Saad B. Omer: Conceptualization, Writing- review and editing. Gregory A. Huber: Conceptualization, Data curation, Formal analyses, Writing- original draft, Writing- review and editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors would like to acknowledge support for the Tobin Center for Economic Policy at Yale University. EKJ and SBO were supported by the Yale Institute for Global Health.

SEB, ASG, and GAH received support from the Institution for Social and Policy Studies and the Center for the Study of American Politics at Yale University.

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2021.10.039 .

Appendix A. Supplementary material

The following are the Supplementary data to this article:

IMAGES

COVID-19 at a Glance: Infographics
COVID-19 Infographics
Infographic: COVID-19
COVID-19 Update
Covid-19 Prevention
What Kids And Families Need To Know About Coronavirus

VIDEO

COVID-19 #funny #experiment
#harshvardhanjain #motivation Harshvardhan Jain motivation speech.covid-19 student #covid19 #viral
SPEECH CONTEST (REIHANNY GALUH ANINDHITA_SMP 2 BANTUL)
Watch: Dr.Jaishankar Reveals India's New Image After Leading COVID Aid Efforts!
SPEECH CONTEST (TALITHA SALSABILA_SMP 2 PLERET)
Covid Inquiry: Boris Johnson 'failed' to work out basic maths during pandemic

COMMENTS

2 Minute Speech on Covid-19 (CoronaVirus) for Students
The severity of Covid-19 symptoms varies widely. Symptoms aren't always present. The typical symptoms are high temperatures, a dry cough, and difficulty breathing. Covid - 19 individuals also exhibit other symptoms such as weakness, a sore throat, muscular soreness, and a diminished sense of smell and taste.
introduction speech about covid 19
Introduction speech about covid 19 - 10077690. Answer: The coronavirus COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War Two.
An Introduction to COVID-19
A novel coronavirus (CoV) named '2019-nCoV' or '2019 novel coronavirus' or 'COVID-19' by the World Health Organization (WHO) is in charge of the current outbreak of pneumonia that began at the beginning of December 2019 near in Wuhan City, Hubei Province, China [1-4]. COVID-19 is a pathogenic virus. From the phylogenetic analysis ...
Introduction
The COVID-19 pandemic is far from over and could yet evolve in unanticipated ways, but one of its most important lessons is already clear: preparation and early execution are essential in ...
Coronavirus disease (COVID-19)
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical ...
Coronavirus disease (COVID-19)
COVID-19 is the disease caused by a coronavirus called SARS-CoV-2. WHO first learned of this new virus on 31 December 2019, following a report of a cluster of cases of so-called viral pneumonia in Wuhan, People's Republic of China.
A Narrative Review of COVID-19: The New Pandemic Disease
After the Spanish flu, now the world is in the grip of coronavirus disease 2019 (COVID-19). First detected in 2019 in the Chinese city of Wuhan, COVID-19 causes severe acute respiratory distress syndrome. Despite the initial evidence indicating a zoonotic origin, the contagion is now known to primarily spread from person to person through ...
Understanding COVID-19
COVID-19 has claimed millions of lives around the world. But we learn more about this disease every day. Scientists are developing tools that promise to slow and eventually help us overcome the pandemic. COVID-19 is caused by a new coronavirus called SARS-CoV-2. There are many types of coronaviruses. Some cause the common cold.
About COVID-19
COVID-19 (coronavirus disease 2019) is a disease caused by a virus named SARS-CoV-2. It can be very contagious and spreads quickly. Over one million people have died from COVID-19 in the United States. COVID-19 most often causes respiratory symptoms that can feel much like a cold, the flu, or pneumonia. COVID-19 may attack more than your lungs ...
Introduction to COVID-19: methods for detection, prevention, response
A novel coronavirus (COVID-19) was identified in 2019 in Wuhan, China. This is a new coronavirus that has not been previously identified in humans. This course provides a general introduction to COVID-19 and emerging respiratory viruses and is intended for public health professionals, incident managers and personnel working for the United ...
Remarks by President Biden on the COVID-19 Response and Vaccination
Speeches and Remarks. South Court Auditorium. Eisenhower Executive Office Building. 12:54 P.M. EDT. THE PRESIDENT: Good afternoon. I've just been briefed by my COVID-19 team on the progress we ...
COVID-19 Pandemic: Knowledge and Perceptions of the Public and
Introduction. In December 2019, the 2019 novel coronavirus disease (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China, followed by a rapid spread all over the world. On March 11, 2020, the World Health Organization (WHO) raised its pandemic alert. As of April 11, 2020, COVID-19 had caused ...
WHO Director-General's opening remarks at the media briefing on COVID
Speeches / Detail / WHO Director-General's opening remarks at the media briefing on COVID-19 - 20 March 2020 ... Good morning, good afternoon and good evening, wherever you are. Every day, COVID-19 seems to reach a new and tragic milestone. More than 210,000 cases have now been reported to WHO, and more than 9,000 people have lost their lives.
a short introduction about covid 19 (speech)
A short introduction about covid 19 (speech) - 33900762. pragyapaul23 pragyapaul23 24.01.2021 English Primary School answered ... See answers Advertisement Advertisement Brainly User Brainly User Answer: A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what ...
The Covid-19 Pandemic -- Finding Solutions, Applying Lessons Learned
Remarks by Commissioner Stephen Hahn, M.D., given electronically (by audio) to the Alliance for a Stronger FDA, on June 1, 2020, and recorded May 30, on video, at the HHS broadcast studio
Frontiers
COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. The Coronavirus (CoV) is a large family of viruses known to cause illnesses ranging from the common cold to acute respiratory tract infection. The severity of the infection may be visible as pneumonia, acute respiratory syndrome, and even death.
How to Write About Coronavirus in a College Essay
Students can choose to write a full-length college essay on the coronavirus or summarize their experience in a shorter form. To help students explain how the pandemic affected them, The Common App ...
Persuasive Essay About Covid19
Step 4: Write the Introduction. In the introduction, grab your reader's attention and present your thesis statement. For example: Introduction: The COVID-19 pandemic has presented an unprecedented global challenge, and in the face of this crisis, many countries have debated the implementation of vaccination mandates.
What you need to know about COVID-19 vaccines
العربية. 25 October 2022. Vaccines save millions of lives each year. The development of safe and effective COVID-19 vaccines are a crucial step in helping us get back to doing more of the things we enjoy with the people we love. We've gathered the latest expert information to answer some of the most common questions about COVID-19 ...
Examining persuasive message type to encourage staying at home during
1. Introduction. The outbreak of the coronavirus disease 2019 (COVID-19) has emerged as the largest global pandemic ever experienced [].Experts have proposed that social lockdown will lead to improvements such as controlling the increase in the number of infected individuals and preventing a huge burden on the healthcare system [, , ].Governments of many countries across the world have ...
Director-General's opening remarks at the media briefing on COVID-19
Christian, back to you. Globally, we are now seeing a plateauing in the number of COVID-19 cases and deaths, with declines in most regions including the Americas and Europe, the two worst-affected regions. But it's an unacceptably high plateau, with more than 5.4 million reported cases and almost 90 thousand deaths last week.
The Critical Role of Health Care Professionals During the COVID-19
We look forward to working with you to achieve that goal. Thank you. Speech by Commissioner Stephen M. Hahn "The Critical Role of Health Care Professionals During the COVID-19 Pandemic" August ...
Persuasive messaging to increase COVID-19 vaccine uptake intentions
1. Introduction. The global spread of COVID-19 created an urgent need for safe and effective vaccines against the disease. However, even though several successful vaccines have become available, vaccine hesitancy in the general population has the potential to limit the efficacy of vaccines as a tool for ending the pandemic.

Products & Resources

Colleges & Courses

Predictors & E-Books

Animation Courses

Top Courses & Careers

Quick Links

Diploma Colleges

Upcoming Events

Other Exams

Top Countries

Student Visas

Engineering Preparation

Medical Preparation

Online Courses

Top Streams

Specializations

Top Providers

2 Minute Speech on Covid-19 (CoronaVirus) for Students

10 Lines Speech on Covid-19 for Students

Short 2-Minute Speech on Covid 19 for Students

Long 2-Minute Speech on Covid 19 for Students

Real-life Story of a Student

Explore Career Options (By Industry)

Data Administrator

Bio Medical Engineer

Ethical Hacker

Data Analyst

Geothermal Engineer

Database Architect

Remote Sensing Technician

Budget Analyst

Underwriter

Finance Executive

Operations Manager

Stock Analyst

Welding Engineer

Transportation Planner

Environmental Engineer

Safety Manager

Conservation Architect

Structural Engineer

Highway Engineer

Field Surveyor

Orthotist and Prosthetist

Pathologist

Veterinary Doctor

Audiologist

Video Game Designer

Radio Jockey

Choreographer

Social Media Manager

Photographer

Copy Writer

Corporate Executive

Multimedia Specialist

Quality Controller

Production Manager

Process Development Engineer

AWS Solution Architect

Azure Administrator

Computer Programmer

Information Security Manager

ITSM Manager

Applications for Admissions are open.

Aakash iACST Scholarship Test 2024

JEE Main Important Chemistry formulas

PACE IIT & Medical, Financial District, Hyd

ALLEN JEE Exam Prep

ALLEN NEET Coaching

SAT® | CollegeBoard

Everything about Education

Download Careers360 App's

We Appeared in

Search form

Understanding COVID-19

Protecting Yourself

What to Look For

Getting Treatment

A Shot of Hope: Vaccines

Related Stories